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The incidence of infections with extended spectrum beta-lactamase (ESBL)-producing E. 
coli in New Zealand is increasing. ESBL E. coli most commonly cause urinary tract 
infections and are seen in both community and hospital patients. The reason for the 
increasing incidence of ESBL E. coli infections is unknown. In this study, 66 urinary ESBL 
E. coli isolates from Otago in 2015 were fully genetically characterised to understand the 
mechanisms of transmission. The ESBL gene, E. coli sequence types, plasmid types, and 
genetic context (e.g. insertion sequences) of ESBL genes were determined by a 
combination of whole genome and plasmid sequencing. A bioinformatic pipeline was 
constructed for the hybrid assembly of Illumina short reads and MinION long reads of 
ESBL-encoding plasmids. Significant diversity of E. coli strains, plasmids, and the genetic 
context of ESBL genes was seen. This suggests multiple introductions of ESBL resistance 
genes or resistant bacterial strains accounts for the increased incidence of ESBL E. coli in 
this low prevalence area. Future studies should investigate modes of transmission of 
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 ANTIMICROBIAL RESISTANCE 
Antimicrobials are the cornerstone of modern medicine. In addition to treating various 
infections, they are essential to prevent infection in many surgical procedures, and to 
manage infectious complications of immunosuppressive treatment plans (e.g. 
chemotherapy) (1). Resistance of bacteria to successive classes of antibiotics has 
emerged and proliferated since the advent of their use, causing treatment failure or 
adverse patient outcomes (2-5). There is also a shortage of newly developed 
antimicrobials to combat resistant strains (6,7). The rise of antimicrobial resistance 
represents an unprecedented threat to modern medicine, with one report commissioned 
by the United Kingdom government estimating that antimicrobial resistance will be the 
leading cause of mortality globally by the year 2050, causing an estimated 10 million 
deaths a year compared to the current estimate of 700,000 deaths per year, and costing 
the world economy $USD100 trillion (6). 
 
 
A specific matter of importance is the development of resistance to the most commonly 
prescribed antibiotics, the β-lactams (5,8). These antibiotics form the backbone of many 
empiric treatment regimens. Their widespread use has exerted a selective pressure, 
leading to the development and spread of resistance (9). In gram negative bacteria, 
production of β-lactamase enzymes, which hydrolyse the antibiotic, is the most common 
mechanism of resistance (9). The spread of resistance has driven the development of 
successive classes of β-lactams, which in turn select for corresponding β-lactamase 
genes (9). One such group of β-lactamases are the extended spectrum β-lactamases 
(ESBLs) which hydrolyse extended spectrum cephalosporins containing an oxyimino 
side chain (i.e. cefotaxime, ceftazidime, ceftriaxone), in addition to penicillins, and 
monobactams, but are inhibited by clavulanic acid (9). ESBL-producing E. coli also 
frequently carry multiple other resistance genes, and as a result are resistant to most 
other classes of antimicrobials (10).  




The World Health Organization (WHO) recently identified ESBL E. coli as one of nine 
resistant bacteria of international concern because of their substantial public health 
impact (1). E. coli are the most frequent cause of urinary tract infections and 
bloodstream infections, and are one of the leading causes of foodborne gastrointestinal 
infections (1, 11, 12).  As empiric therapy is often ineffective for patients with these 
cephalosporin resistant infections, infection is associated with increased mortality, as 
well as associated additional costs in hospitalization, antimicrobial therapy, and medical 
care compared to cephalosporin susceptible infections (1). In addition, the treatment of 
ESBL-producing E. coli infections frequently requires the use of carbapenems, which are 
more expensive, less accessible, and of exceptionally broad spectrum. The use of 
carbapenems also applies a selection pressure for the emergence and spread of 
carbapenemase producing bacteria, which can be resistant to all available antimicrobials 
(1,9). In a 2014 report, five out of six WHO regions reported >50% resistance of E. coli to 
3rd generation cephalosporins, with the highest reported resistance rate being 82% (1). 
 
 
In comparison, the prevalence of resistance in New Zealand is relatively low but is 
increasing. In 2016, ESBL producing Enterobacteriaceae were isolated from clinical 
specimens of only 11.1 people per 100000 population in New Zealand, however this had 
more than doubled between 2007 and 2016 (13). Over the same period,  there has been 
a concomitant increase in the proportion of ESBL-producing Enterobacteriaceae that are 
E. coli (52.0% in 2007 to 74.1% in 2016) and a decrease in the proportion that were 
Klebsiella spp. (42.0% in 2007 to 22.3% in 2016) (13). Waitemata, Counties Manukau, 
and Auckland District Health Boards (DHBs) constitute high prevalence areas, and the 
DHBs of Lakes, Northland, Waikato, Capital & Coast/Hutt and Taranaki have seen 
significant increases in the incidence of ESBL-producing Enterobacteriaceae between 
2009 and 2014 (13). The Southern DHB is a low prevalence area in comparison (13). 
However, in Otago, the number of ESBL E. coli isolates per year implicated in urinary 
tract infections doubled between 2012 (40 isolates/year) and 2015 (82 isolates/year). 
 
 




 GENETIC UNDERPINNING OF ANTIMICROBIAL RESISTANCE 
In order to understand the increase in the overall incidence of ESBL E. coli, it is 
important to consider the genetic diversity that underlies the ESBL phenotype. High 
diversity would indicate multiple introductions, while low diversity would indicate a 
single introduction or a limited number of introductions with clonal expansion. An 
understanding of this genetic diversity is essential to identify reservoirs, sources, and 
modes of transmission of ESBL E. coli and thereby implement the most effective control 
measures. There are several levels of diversity to consider: E. coli clonality including 
sequence type, ESBL genotypic (gene) variants, plasmid type, and the genetic context 
(e.g. insertion sequences) of the ESBL gene. 
 
 
Firstly, clones are highly related bacteria with a recent common ancestor. Different 
clones are defined by single nucleotide polymorphisms in the core genome (14). The 
clonality of isolates can be identified by molecular typing procedures, such as multilocus 
sequence typing (MLST) to define sequence types of E. coli. There is not a single 
sequence type, but multiple sequence types responsible for ESBL production in E. coli 
worldwide. However, there are some predominant sequence types, which are highly 
virulent, highly transmissible, and multidrug resistant, that have an evolutionary 
advantage over other E. coli, which have contributed to the success of ESBLs. For 
example, ST131 is the most common worldwide as well as in New Zealand (13 -17). 
Other common sequence types of ESBL E. coli include 69, 73, 95, 38, 393, and 405 (2,15). 
 
 
The emergence of ESBL-producing E. coli ST131 is particularly relevant for the 
treatment of urinary tract infections, one of the most common infections worldwide,  
due to its increased adherence and biofilm formation ability, and frequent resistance to 
fluoroquinolones, a commonly used treatment for  urinary tract infections (3,4,15,16). 
Sequence types 69, 73, and 95 are also commonly associated with urinary tract 
infections (2). Urinary tract infections are also the most common infection caused by 
ESBL E. coli in New Zealand, consistent with the rest of the world (13). 
 




Secondly, there are multiple families of genes that encode an ESBL. There are over 350 
ESBL genotypes, which are grouped into TEM, SHV, and CTX-M type enzymes, as well as 
the less common VEB, Toho-1, Toho-2, and OXA enzyme types (5,9,18,19). TEM and SHV 
ESBLs arose first by point mutations in TEM and SHV genes encoding narrow spectrum 
β-lactamases and became widespread in the 1980s (15,18). So far, 196 TEM variants 
have been identified, many of them (n = 84) displaying an ESBL phenotype. SHV ESBLs 
evolved from narrow-spectrum SHV-1 or SHV-11 β-lactamases by point mutation; 
among the existing 143 SHV variants, 43 display an ESBL phenotype (10). Since the turn 
of the millennium, CTX-M types have emerged and become dominant globally (5,15,18-
20). The diverse CTX-M type ESBLs are classified into 6 groups - 1, 2, 9, 25, 8, and 19LUC 
- by amino acid sequence similarities (5,15,18). Globally, the most widespread enzymes 
are CTX-M-14 (group 9) and CTX-M-15 (group 1); these have also been the most 
common in New Zealand (19-22). Different genes are more common in different parts of 
the world (15,19,22). For example, CTX-M-2 is prevalent in South America but is rarely 
seen in the United Kingdom (19,22-24). The most dominant ESBL type in a particular 
region can change over time (19,22). In Japan, between 2007 and 2012, CTX-M-27 
overtook CTX-M-14 as the predominant ESBL type (25). In China between 2009 and 
2014, CTX-M-55 overtook CTX-M-15 as the second most common genotype behind CTX-
M-14 (26,27). Up to date studies on the proportions of CTX-M gene types are therefore 
important to gauge any trends and emerging epidemics. 
 
 
Associations between ESBL encoding genes and sequence types have been well 
documented worldwide. Overall, CTX-M-15 is the most common ESBL subtype globally. 
In most countries in the world a strong association between ST131 and CTX-M-15 has 
been observed; being especially common in North America and Europe compared to 
Asia (14-17,22,28). E. coli ST131 is likely responsible for the global success of CTX-M-15 
(14-17,22). In 2013 an ESR study of 224 ESBL-producing E. coli from New Zealand, 125 
(55.8%) were CTX-M group 1, which includes CTX-M-15, and 97 (43.4%) were CTX-M 
group 9, which includes CTX-M-14; of the ST131 isolates, there was almost an equal split 
between group 1 and group 9 CTX-M ESBLs (29). In the 2016 New Zealand nationwide 
study by ESR, 57.9% (62/107) of H30 ST131 had a group 1 CTX-M ESBL, and 42.1% 
(45/107) had a group 9 CTX-M ESBL, and an association between the H30Rx ST131 
subclone with CTX-M-15 was found (13). Conversely, an association between CTX-M-27 




and ST131 has been seen in some Asian and European countries such as Japan, China, 
and Germany (22,30-37).  
 
 
Thirdly, bacterial genomes are plastic and are subjected to point mutations, genome 
rearrangements (i.e. deletions and insertions, etc.), to localized recombination events, 
and to acquisition and loss of mobile genetic elements (14). Antibiotic resistance genes 
encoded on mobile genetic elements may spread at two levels: first some mobile genetic 
elements are able to transfer between bacterial cells (conjugative mobilizable plasmids 
and conjugative integrative elements), and second some mobile genetic elements are 
able to transfer between DNA molecules (insertion sequences, transposons, gene 
cassettes, and integrons) (2,14,38). The mobile genetic elements encoding resistance 
mechanisms may vary between isolates of the same sequence type (39). The spread of a 
mobile genetic element may be more important for the increased prevalence of 
antimicrobial resistance genes than the spread of a particular bacterial clone (39). 
Moreover, resistance genes and mobile genetic elements are often found clustered 
together in large multi-resistance encoding regions in plasmids or ‘resistance islands’ in 
the chromosome. Consequently, bacteria are able to acquire a combination of resistance 
genes, allowing co-selection, and as a result, the success of a particular resistance gene is 
dependent on its genetic context (38). Thus, characterization of the genetic context, 










Figure 1:  Examples of mobile genetic elements and processes involved in 
intracellular mobility or intercellular transfer of antibiotic resistance genes. 
Intracellular movement of mobile genetic elements is shown by thin black arrows. Large 
green arrows indicate horizontal transfer or plasmids or gene cassettes.  A: bilateral 
insertion of insertion sequence elements around a resistance gene allows mobilisation 
as a composite transposon; B: unit transposon allows mobilization of resistance genes 
between plasmids or plasmid and chromosome; C: gene cassettes insert into integrons; 
D: integrative conjugative elements (ICE) capable of intra- or intercellular chromosomal 
integration; E: transposons and integrons can move into other plasmids or chromosome 




ESBL genes are carried by mobile genetic elements, including plasmids, transposons, 
insertion sequence elements, and integrons. The various mobile genetic elements are 
illustrated in Figure 1 (40). Plasmids are self-replicating, extrachromosomal circular 
DNA, some of which can move between different bacterial strains, or even species, by 
conjugation (41). Plasmids show high degrees of plasticity, carrying several types of 
mobile elements, such as gene cassettes, integrons, insertion sequence elements, and 
transposons, which can transfer ESBL genes between plasmids and can also integrate 




within the bacterial chromosome (14,38,42). Insertion sequences are the most abundant 
transposable elements, and the smallest mobile genetic element that carries the genetic 
information necessary for their own transposition; insertion sequences encode an 
enzyme, named transposase, which is responsible for mobilization. The transposase 
recognizes inverted repeat (IR) sequences at the ends of the insertion sequences and is 
responsible for the integration process (38,42-44). Insertion sequences cause insertion 
mutations, genome rearrangements and enhance the spread of, and expression of, 
resistance and virulence genes within species (38,42-44). Unit Transposons are larger 
than insertion sequences and encode resistance genes as well as transposition genes 
(Figure 1B) (14,38,42-44). There are three types of transposition: 1) two copies of the 
same insertion sequence bracketing a mobilized fragment, that form a composite 
transposon (Figure 1A); 2) mobilization by a single copy of the insertion sequences of 
adjacent sequences, known as rolling-circle transposition, mediated by insertion 
sequences including IS91 and ISCR-like elements; 3) mobilization by a single copy of an 
insertion sequence of adjacent sequences through a ‘‘one-ended transposition’’, where a 
single insertion sequence recognizes its own inverted repeat left (IRL) and a secondary 
sequence used as inverted repeat right (IRR) in sequence other than its own, the latter 
defining the right extremity of the DNA fragment mobilized (44). This third mobilization 
mechanism has been observed with Tn21 and ISEcp1 (44). 
 
 
Plasmids, transposons, and insertion sequence elements can carry integrons which in 
turn can accumulate multiple gene cassettes (41). Gene cassettes consist of a ribosome 
binding site and attC recombination site preceding the gene; they do not encode the 
mechanism for their own movement, and are the smallest mobile genetic elements 
associated with antibiotic resistance. While gene cassettes can exist as circular 
molecules, they are usually inserted into integrons (Figure 1C) (43). Integrons contain 
an intI gene, an attI recombination site, and a Pc promoter. The intI gene mediates the 
insertion or release of gene cassettes by encoding an intI integrase that catalyses site-
specific recombination between the attI1 site and the attC site of the gene cassette. 
Several cassettes can be integrated into the same integron, and chromosomal integrons 
can form a reservoir of transferable gene cassettes encoding antimicrobial resistance 
and virulence factors, resulting in resistance to multiple classes of antimicrobials (41-
44).  




Plasmid transmission has played a major role in the spread of ESBL resistance genes 
(4,14,15). Plasmids are extrachromosomal circular DNA, which replicate independently, 
and some can be transferred between bacteria by conjugation (14,38). Plasmids can be 
classified by their incompatibility type (45-48). Plasmid incompatibility is the inability 
of two co-resident plasmids with the same replication and partitioning elements to be 
stably inherited in the absence of continued selection pressure (46-48). Thus, 
incompatible plasmids belong to the same incompatibility group (Inc type) (47). Inc type 
can be determined by simple multiplex polymerase chain reaction (PCR) of specific 
replicon sequences (45). Several replicons can also exist in one plasmid- called multi-
replicon plasmids; this phenomenon is common in IncF groups (47-49). Determining the 
incompatibility type (Inc type) of plasmids is useful as certain Inc types have been 
associated with antimicrobial resistance and virulence (45).  
 
 
ESBL genes are often encoded on plasmids, and CTX-M genes have been found on 
plasmids of almost all major incompatibility groups (plasmid types) (18). The spread of 
CTX-M ESBL genes is mainly associated with incompatibility group F, especially the 
IncFII replicon (19,50,51). IncF plasmids have a narrow host-range, unlike broad host-
range replicon plasmids such as IncN, IncI1, and IncL/M that have greater disseminative 
potential due to their ability to spread the resistance gene across species (14). IncF 
plasmids are heterogeneous, varying in size (50 to 200 kb), carrying different resistance 
determinants, and different (combinations of) divergent replicon types. Epidemic 
resistance plasmids belonging to IncF with divergent replicon types such as FIA, FIB, and 
FII show high conjugative ability, high transmission rates among Enterobacteriaceae, 
and the tendency to acquire multiple resistance genes, which allows co-selection 
(4,14,15,19,50-52).  The pandemic CTX-M-15 is mainly associated with IncFII. However, 
there have been recent reports in Turkey, Germany, Egypt, and India, of high incidence 
of IncFIA and IncFIB plasmids (alone and in combination) (52-57). Broad host range 
plasmids IncN, IncI1, and IncL/M have also been involved in the dissemination and 
spread of CTX-M enzymes (19). IncN plasmids conjugate with high frequency, are found 
in the bacterial flora of humans, animals and the environment (constituting reservoirs of 
infection), and have been associated with CTX-M-1 (58). SHV-type ESBLs have also been 
identified on a variety of plasmids, from narrow range (IncF, IncI1, and IncX3), to broad 
range (IncA/C, IncHI2) (59). These plasmid types have been associated with the 




dissemination of SHV-2, SHV-5 and SHV-12. TEM-type ESBLs have been found to be 
strongly associated with IncA/C plasmids (51,60). The exception to this is the TEM-52 
ESBL gene, which has been mainly associated with IncI1 plasmids (44,51,60). IncI1 
plasmids are of particular interest as they are highly transmissible, they are globally 
spread among E. coli populations from humans and animals, and they appear to be 
widely distributed among different members of the Enterobacteriaceae family (42). The 
New Zealand ESR annual surveys do not include plasmid typing, this denotes a gap in the 
knowledge of ESBL E. coli transmission in New Zealand (29). 
 
 
The mobilization of β-lactam genes has largely been driven by insertion sequences 
ISEcp1, ISCr1, and IS26 (2,30,44,61,62). Certain plasmid replicon types such as IncF, 
IncN, and IncK are associated with certain insertion sequences (e.g., ISEcp1 or ISCR1), 
and show greater ability to mobilize CTX-M genes. Insertion sequence elements have 
been shown to act as strong promoters of CTX-M gene expression (19). In addition, 
elevated temperature and antibiotic selection pressure have been shown to increase the 
mobilization frequency of ISEcp1 and the ESBL genes present downstream from it; 
interestingly, cefotaxime, ceftazidime, and piperacillin enhanced transposition, whereas 
amoxicillin, cefuroxime, and nalidixic acid did not (4,30,63).  ISEcp1 is the most widely 
found insertion sequence upstream of different CTX-M genes (associated with all 
clusters of ESBLs except CTX-M-8), followed by ISCR1 (associated with members of the 
CTX-M-2 and CTX-M-9 groups), IS10, and less commonly IS26 (18,30,62,64-67). IS1 and 
IS10, and even ISCR1 and IS26, have been described interrupting ISEcp1 (18,64). Less is 
known about sequences downstream of CTX-M genes (18,30,44). Downstream of the 
ESBL genes, different insertion sequence elements have been found in different CTX-M 
groups. In the CTX-M-1 cluster, sequence orf477 and mucA have been reported, while in 
the group 9 cluster IS903 is common, and insertion sequences are sometimes truncated 
(Tn07 and Tn13) (64,65,66). The genetic distance between insertion sequences and the 
CTX-M gene can influence the level of gene expression and hence the level of resistance 
(18,30). IS26 and ISEcp1 are theorised to be important in Enterobacteriaceae multi-
resistant plasmid evolution (43,61). IS26 plays a major role in the mobilization and 
expression of SHV, being found flanking the gene in composite transposons (43). The 
TEM-like ESBL genes are often carried by three of the earliest bacterial transposons 
identified. The closely related transposons identified as the carriers of TEM genes were 




originally designated TnA, and later delineated as Tn1, Tn2, and Tn3. The differences 
between these transposons are limited to short regions flanking the res site (44). Tn1 




While in theory resistance genes associated with particular mobile elements can be 
acquired from any source, in practice ecology affects the gene flow. The inappropriate 
use of antibiotics in medicine and agriculture (animal livestock) enforces a selective 
pressure (68). Antibiotics used in humans and animals can be released into the 
environment through sewage, wastewater, and agriculture (68). Exposure to antibiotics 
in the environment selects for mobilization of resistance genes (4,15,43). Antibiotic 
producing microbes also occur naturally in the environment (68). Plant, soil, wildlife and 
livestock colonization can constitute reservoirs and sources of antibiotic resistance 
genes and/or bacteria (68). ESBL producing bacteria have been identified in agricultural 
(e.g. animal faeces) and industrial waste (human sewage) (68). Biological evidence of 
clonal linkage can be utilized to support epidemiological evidence (39). 
 
 
Control strategies include wastewater management (reduced microbial and 
pharmaceutical pollution), agriculture management (reduction in antibiotic used, 
treatment of animal waste and reduced access of effluent to water courses), and medical 
practice management (appropriate antibiotic use, degradable pharmaceuticals). 
Tracking the spread of infection from person to person is important to define 
transmission rates, incubation periods, infection duration, antibiotic resistance, 
reservoirs, sources, and high-risk groups in order to control and predict transmission 
and the outcome of interventions. Both the WHO and a recent United Kingdom report 
have stressed the importance of global surveillance (1,6).   
 
 




In order to implement effective control measures the molecular epidemiology must be 
assessed to postulate the source and route of transmission (68). Clusters of cases caused 
by molecularly similar isolates can be analysed to determine the origin (39). A high level 
of clustering, wherein a few dominant ESBL genotypes, sequence types, plasmid types 
and common genetic context is observed, indicates a single, or limited number of point 
source introductions, with clonal expansion and MGE transmission (27,39,69-74). Low 
level of clustering of isolates, indicates multiple introductions, and may reflect the 
acquisition of drug resistance through inadequate treatment strategies, rather than 
transmission of highly virulent drug resistant strains (39,69,70,74). 
 
 
 LABORATORY METHODS FOR CHARACTERISING RESISTANCE  
It is indisputable that accurate information regarding the genetic context and diversity 
of resistance genes are essential to formulating appropriate and effective control 
measures (1,6). However, this information can be difficult to define in a timely manner 
for practical reasons as there are many plausible infection pathways and sources (75). 
Since epidemiologically related pathogens will also be closely related genetically, 
efficient methods of genetic analysis are required for this purpose (75). Sequencing 
technology has developed rapidly over the years since the 1960s, from Sanger 




  First Generation Sequencing 
The first major breakthrough in sequencing technology was Sanger Sequencing, in which 
chain terminating dideoxynucleotides (ddNTPs) are incorporated into a DNA extension 
reaction at a concentration such that DNA strands varying by a single nucleotide length 
for the whole length of the required strand are produced. The ddNTPs are labelled so 
bases can be differentiated, thus base-calling the whole strand. Initially, ddNTPs were 




radiolabelled (four reactions for each base pair and run on a polyacrylamide gel) before 
fluorometric labelling was introduced (single reaction for all base pairs) (76). 
 
 
There are major limitations to Sanger Sequencing: it has a long turn-around time, it is 
labour-intensive, it has a high cost per base pair and a short-read length of <1000 bases 
(77). This is especially true for whole plasmid or genome resolution which requires a 
large amount of data for mapping. In a previous study we were unable to completely 
resolve the ESBL gene types by Sanger Sequencing (ABI BigDye Terminator [version 3.1; 
Applied Biosystems, Foster, CA, USA] technology), probably due to the read length 
limitations of Sanger Sequencing (78).  
 
 
  Second Generation Sequencing (SGS)  
SGS, which invariably involves massive parallel sequencing, made efficient whole 
genome sequencing at a lower cost possible, through modern computational methods.  
Many methods and technologies have been developed, all with deficiencies in 
detecting homopolymer sequences. These include ion semiconductor sequencing (Ion 
Torrent, Life Technologies), as well as the now discontinued pyrosequencing technique 
(454, Life Sciences) and the Sequencing by Oligonucleotide Ligation and Detection 
(SOLiD) system (Applied Biosystems). The platform relevant to this study is Illumina 
Sequencing (San Diego, CA) (76). 
 
 
The Illumina Sequencing platforms use the principle of bridge amplification on a solid 
phase substrate (79,80). DNA is enzymatically fragmented and modified by ligation at 
both ends with adaptors (oligos to attach to the flow cell) and indices (to identify 
samples for multiplexing). The single stranded DNA library is loaded on to a chip which 
has synthetic oligonucleotides that function to capture the complementary adaptors on 
the DNA strands. Next bridge amplification takes place, wherein the DNA strand bends 
to a bridge shape as the adaptor at the other end of the strand attaches to another 
complementary oligonucleotide on the flow cell and a polymerase creates a 




complementary strand with unlabelled nucleotides, followed by denaturation. This 
creates distinct clonal clusters (several million of them in each channel) of single-
stranded templates anchored to the substrate. Sequencing then begins with the addition 
of fluorescently labelled reversible terminator deoxy nucleotide triphosphates 
(dNTPs)of all four bases, primers and DNA polymerase (79,80). Reversible terminator 
dNTPs are designed so that the fluorophore occupies the 3′ hydroxyl position, which 
needs to be cleaved away for polymerization to continue. Thus, after the first base 
incorporation cycle, laser excitation is used to emit fluorescence from each cluster, and a 
digital picture is taken with a CCD camera. The blocking fluorescent tags are then 
enzymatically removed and the next complementary reversible terminator dNTP added, 
continuing the cycle until the sequence of the fragments are determined (76). The 
natural competition of the four bases minimizes incorporation bias and reduces raw 
error rate (80).  
 
 
Illumina Inc. produces a number of devices using this technology. The platform used in 
this study - recommended for sequencing of microbial genomes - is the Illumina NextSeq 
500. This platform has a very high accuracy (0.1% error rate), a sequencing time of 30 
hours, a preparation time of 8 hours, and has an output of 100-120 Gb/run output, the 
cost of platform is $USD250,000, it measures 59 × 53 × 64 cm and weighs 83kg (76,80). 
Thus, second generation short read sequencing techniques have allowed whole genome 
sequencing rapidly and affordably compared to first generation sequencing. However, it 
has not overcome the disadvantage of producing short reads.  Averaging at read lengths 
of 150 bp, SGS has proved deficient in resolving assembly continuity (i.e. positions of 
elements in a large genomic structure such as a plasmid) due to long repetitive 
elements, copy number alterations and structural variations. Full portrayal of these 








  Third Generation Sequencing (TGS) 
TGS technologies have recently been launched commercially. TGS overcomes the 
deficiencies in SGS by facilitating sequencing of single molecules, producing long reads 
and negating the requirement for DNA amplification (76). TGS improves the read length 
from the scale of tens of base pairs to over 10000 base pairs per read, shortens the turn-




 Pacbio Sequencing 
Currently, the most commonly used and well validated TGS platform is the single 
molecule real time (SMRT) platform from Pacific Biosciences, commonly referred to as 
Pacbio sequencing (76). This technology relies on a chip of arrays of tens of thousands of 
microfabricated nanostructures known as zero-mode waveguides (ZMWs). Each ZMW is 
illuminated from below with a wavelength of light that is larger than the aperture of the 
ZMW, thus penetrating only the lower 20-30nm of the ZMW and acting as a powerful 
microscope. As phospho-linked nucleotides are incorporated by a DNA template-
polymerase complex immobilized at the bottom of the ZMW, the phosphate chain is 
cleaved, releasing the attached fluorophore and a specific light pulse is produced. The 
detection volume in the order of nanometres reduces background noise (76,84). 
 
 
Pacbio offers the advantage over SGS of reasonably accurate long reads in the order of 
10 - 40 kb, in a shorter amount of time (4 hours sequencing time), at 0.5-1 Gb per run. 
However, it is still expensive both upfront ($USD750000 instrument cost) and per 
output, it is not portable with instrument dimensions of 200 × 77 × 158 cm and 1091 kg 
weight, and it has a higher error rate than Illumina at 14%. In terms of accuracy, Pacbio 
has difficulties with resolution of repetitive genomic regions and regions of high GC 
content, though it can detect modified DNA bases (e.g. DNA methylation patterns) (76). 
 
 




 Nanopore Sequencing 
The most recent development in TGS technology is the application of nanopores by 
Oxford Nanopore Technologies (ONT) in the MinION platform (76,82,85).  Nanopore 
sequencing is a based on the principle of molecules causing characteristic changes in 
current when passing through a nanopore in a conducting fluid with a voltage potential 
applied across it. Specifically, electrodes are immersed in chambers on either side of the 
membrane, setting up a biased voltage across the membrane. An ionic current signal is 
generated as electrolyte ions pass through the nanopores, which is monitored. When a 
DNA molecule (negatively charged) passes through a nanopore by drift diffusion, it 
blocks the pore, and therefore interrupts the current signal. Different base pairs cause 
characteristic fluctuations in the current (time and amplitude), which can be measured 
to identify the base pairs (85). 
 
 
The characteristics of the pore affect the performance as a sequencer. The nanoscopic 
pore can be solid-state biological transmembrane protein channels embedded in a 
matrix. Translocation of DNA through the pore must be controlled by coupling an 
enzyme motor to the nanopore (or another method such as utilizing nucleotide labelling, 
hairpin termination, or positively charged residues in the nanopore)  to allow single 
nucleotide resolution as natural diffusion is too rapid (>10 nt/μs through solid state 
pores and >1 nt/μs through biological pores) to differentiate natural current noise from 
thermodynamic fluctuations (82,86,87). The size of the pore also affects sequencer 
performance. This is because it determines the number of nucleotides present in the 
pore at a given time which contribute to the current generated, so the smaller the pore 
the less noise generated (86). The stability of the pore in different pH and temperature 
(which may increase during a run) is important for real world use (86). 
 
 
1.4.3.2.1 Biological Nanopores  
Biological nanopores are transmembrane protein channels which are inserted into 
planar lipid bilayers, liposomes, or other polymer films, and occur commonly in nature 




(85,88). They are desirable because pores of precise size and structure (at the atomic 
level) can be designed using molecular biology techniques (by altering amino acids in 
existing natural biological membrane sequences) and produced in large numbers. This is 
not possible with available semi-conductor technology as of yet (85,87). 
 
 
The first biological nanopore that was proposed for TGS was the alpha haemolysin of S. 
aureus, an exotoxin which is a 232.4 kDa transmembrane channel that can insert itself 
into planar lipid bilayers, forming a pore measuring 1.4 nm at the narrowest point with 
a 3.6-nm diameter cap and a 2.6-nm diameter transmembrane β-barrel (85). This makes 
it close in size to a single stranded DNA molecule. Though this nanopore has advantages 
in that can it remain functionally stable at temperatures close to 100°C within a wide pH 
range (pH 2–12), it also has disadvantages in the size being too small for molecules 
larger than ssDNA and RNA, and too long to distinguish individual nucleotides in single 
long-chain DNA molecules directly (85). 
 
 
Mycobacterium smegmatis porin A (MspA) is an outermembrane porin which enables 
hydrophilic nutrient entry in M. smegmatis. With a pore measuring ∼1.2 nm in diameter 
and ∼0.5 nm in length, it has advantages over alpha haemolysin in that the smaller 
diameter facilitates trinucleotide sets, its octamer configuration can be used to sequence 
four nucleotides simultaneously,  and it is also more robust to larger pH variations (0-
14) at higher temperatures (100oC for 30min) (85-87,89).   
 
 
Bacteriophage phi29 has an advantage over the previous two pore types in that it is 
wide enough to admit dsDNA, proteins and DNA complexes (3.6 nm-6 nm diameter), has 








Curlin sigma S-dependent growth (CsgG) is the most recent nanopore in commercial use 
(90). In nature Curli are bacterial surface appendages used for biofilm formation. CsgG is 
a 262-residue lipoprotein located on the outer membrane that is a prerequisite soluble 
accessory protein for the secretion of CsgA and CsgB, which form an ungated peptide 
diffusion channel. CsgG in its channel formation contains a 36 stranded β-barrel domain, 
forming a transport complex 120 Å (12 nm) in width, 85 Å in height, and a 40 Å inner 
diameter. There is a restriction formed of three rings of concentric amino acid rings 
measuring 9 Å in diameter that may guide the extended polypeptide substrate through 
the secretion pore (90-93). 
 
 
1.4.3.2.2 Solid State nanopore 
Though solid state nanopores are not in use today for long read sequencing, they will 
probably be the future of nanopore sequencing. This is because of the potential to 
inexpensively produce high density arrays of nanopores with superior and modifiable 
chemical, physical and thermal properties, thereby being more robust and durable. They 
may also be more easily paired with other electronic devices. Focused electron beams 
are used to make solid state nanopores. However, the technology does not currently 
exist to fabricate sub-nanometre thick membranes with the control required, with no 
current leakage through pinholes in ultrathin membranes. Types of materials that show 
promise include SiN membranes, which have a high chemical resistance and low 
mechanical stress and are made using an optimized  low-pressure  chemical  vapor  
deposition, Al2O3 membranes, with which there is greater control over membrane 
thickness, and graphene, which has  superior mechanical, electrical and thermal 
properties and natural thickness comparable to nucleotide distance. The main problem 
however is the fact that they are limited to sensing differences in size alone, instead of 
chemical properties. This may be overcome by creating hybrid nanopores (85,87). 
 
 




1.4.3.2.3 The MinION platform 
The principle of nanopore biosensors was first conceived in the 1990s (82,85). Proof of 
concept studies for the use of nanopores coupled with enzyme motors for controlled 
nucleotide translocation and detection were undertaken in 2005-2010. In 2012 the first 
platform was announced by Oxford Nanopore Technologies, began beta testing in 2014, 
and was only released for commercial use in 2015. As is evident, this technology is still 
in development with improvements being made, methods being finessed, and updates 
being released in real time (76,82,85). 
 
 
The platform produced by ONT is known as the MinION, a biological nanopore 
sequencing USB device, the latest (R9) of which uses an engineered/optimized CsgG 
derived from E. coli (82,90,93). The MinION plugs into a desktop computer or laptop 
using a high-speed USB 3.0 cable, weighs 90 g, and measures 10 × 3 × 2 cm, making it the 
first portable sequencing device (83). One flow cell can be used to produce 10-30 Gb of 
data, and a starter pack including a MinION device, reagents, and flow cell only costs 
$USD1000. Library preparation time can be as little as ten minutes for some kits. 
Computational requirements include Windows 7 or above, >8GB RAM and >128GB disk 
space, and the MinKNOW software which carries out data acquisition, real-time analysis, 
and feedback. The MinION flowcell has 2048 nanopores arranged in 512 channels, 
allowing up to 512 independent DNA molecules to be sequenced simultaneously. When 
a run is started wells in each channel are tested, grouped, and ranked in descending 
order from the most active (G1) to the least (G4). The default run time is 48 hours. G1 is 
used in the first 24 hours, followed by the other groups (82,83,90,93). 
 
 
Library preparation is required, though the method complexity and time required 
differs from kit to kit. Library preparation can involve DNA fragmentation, with methods 
varying from Covaris g-tube shearing, needle shearing, or enzymatic fragmentation 
(transposase with barcoded adaptors attached to ends in the same step in the rapid 
barcoding kit). There is end repair, dA tailing, and hairpin adaptor ligation in some kits. 
All kits involve the addition of sequencing adaptors and bead purification to remove 
nucleotides and enzymes. The rapid sequencing kits have the shortest library 




preparation time and simplicity, though problems of barcode cross-over between runs 
using all barcoding kits have been reported (94). There are three sequencing 
chemistries: 1D, where only one strand is sequenced, 2D (now discontinued), where 
both strands are sequenced by joining the complementary strands by adaptor ligation, 
and 1D2, where both strands are sequenced sequentially as the complementary strand is 
tethered to the membrane (82,83,90,93). 
 
 
The following are the reasons this new technology is so promising compared to Pacbio 
and SGS: portable device size, lower price, longer read length, and shorter library prep 
time. These features can make long read sequencing accessible to many laboratories and 
can be used in the field. Several studies have already been done where the MinION was 
used in the field, or methods developed for use in the field. For example, it was used in 
the detection and characterization of Ebola virus during an outbreak in Liberia, and in 
the detection of Zika virus and Dengue virus from clinical samples (83,95-97). However, 
the MinION shows poorer sequence accuracy than Pacbio systems currently. Accuracies 
ranging from 65%-88% have been reported, though sequencing alignment accuracy has 
reportedly improved with newer kits and flow cell versions with R9 reaching 97% for 
2D/1D2 experiments (83). Though maximum accuracy is still slightly lower for 1D 




 WHOLE GENOME SEQUENCE ASSEMBLY AND BIOINFORMATICS 
The accuracy of genome assemblies also depends greatly on the downstream 
bioinformatic analysis methods and tools used. Though the long reads of TGS overcome 
the problem of low positioning accuracy of SGS, they lack accuracy. Using short read 
only assembly alone results in more fragmented assemblies. Using TGS reads alone for 
assembly results in assemblies with lower accuracy, even with polishing steps. The 
combination of these two methods is therefore beneficial. With hybrid assembly the TGS 
sequences are used as scaffolds for the more accurate SGS sequences. This results in 








Hybrid assembly involves the use of several bioinformatic tools in a sequence of steps; 
forming a ‘bioinformatic pipeline’. Firstly, the raw signal generated by the MinION (.fast5 
files) must be base called, which produces .fastq files. Albacore (Oxford Nanopore 
Technologies), Nanocall, Deepnano, Chiron, and Deepbinner are examples of different 
base callers (103-106). If several samples are run at the same time using biological 
barcodes, they must be demultiplexed. Other adaptor sequences must also be removed. 
Porechop is an example of a command-line program that is able to do this (107). Some 
base callers such as Albacore (Oxford Nanopore Technologies) and Deepbinner also have 
the ability to demultiplex (106). At this stage reads can also undergo error correction 
using a program such as Nanopolish (108). The long read and short read sequences must 
then be assembled. Several assemblers have already been developed, each with 
advantages and disadvantages. There are long read only assemblers such as 
Miniasm/Minimap, which is fast (as little as 2 minutes) but has a high error rate, and 
Canu which is more accurate but has a longer turn around time (up to 2 hours) (99,109). 
There are also assemblers that can be used for short read only assembly such as SPAdes 
(110). SPAdes and BWAMEM are examples of programs that can be used for hybrid 
assembly (110,111). Racon and Pilon are consensus based assembly error correction 
software optimized for long reads and short reads respectively (112,113).  
 
 
 WGS IN EPIDEMIOLOGICAL STUDIES 
SGS and TGS (including hybrid methods) allow for efficient whole genome sequencing 
(WGS) of bacteria (76). WGS provides an advantage over older methods of detection for 
epidemiological studies by allowing identification of resistance genes, virulence factors, 
plasmids, and phylogenetic linkages (including multilocus sequence typing [MLST]) in 
one experiment, thereby allowing transmission route elucidation up-to host-host scale, 
especially in combination with epidemiological population information (75,79).  




However, it is important to note that there are many deficiencies in using WGS alone for 
epidemiological studies.  WGS may provide insufficient signal in infections where the 
mutation rates are low compared to generation time (75). Conversely, there is the 
possibility of false negative clustering in bacteria with high diversity such as E. coli 
(114). Genomic information also does not necessarily translate to gene expression and 
transcription, making WGS less accurate than phenotyping in predicting antimicrobial 
susceptibility due to weak promoters, low copy numbers or unknown mutations 
(encoded but not phenotypically expressed) (77,115). 
 
 
There are also bioinformatic difficulties in WGS. The analysis is highly dependent on the 
quality of sequencing, genome assembly and the chosen reference genome (77). 
Resistance genes absent in the reference database may be missed when comparing with 
WGS data (77,115). High computational requirements feature into the costs of WGS that 
may be overlooked next to instrument and running costs (77).  Costs for data storage – 
in the gigabytes for just one sample - should be considered (cloud-based storage may be 
impeded by bandwidth, transfer connection strength and cost) (77). Data security and 
confidentiality should also be taken into consideration (77). Another limitation is the 
lack of standardization, validation, and comparisons, with all the different bioinformatic 
tools available (77). Currently the ‘bioinformatic bottleneck’ may be the biggest 
impedance for WGS (77). Development of user friendly bioinformatic pipelines to 




An increasing incidence of ESBL producing Escherichia coli infections has been seen in 
Otago. I hypothesized that this increase in incidence is due to the clonal spread of one 
(or a small number of) strains or ESBL-encoding mobile genetic elements. Therefore, the 
aim of this study was to determine the genetic diversity of ESBL-producing E. coli 
causing urinary tract infections in Otago over a 1-year period (2015-2016). The 
phylogenetic relationships of bacteria were determined by whole genome sequencing. 




To identify the genetic context of the ESBL gene, a bioinformatic pipeline was developed 
to construct complete plasmid sequences by hybrid assembly of short read sequences 
(Illumina NextSeq) and long read sequences (MinION Oxford Nanopore Technologies). 
This information will inform future studies to identify sources and reservoirs of ESBL E. 
coli within the Otago region. It will also provide a bioinformatic pipeline to assist with 
the analysis of plasmids encoding resistance genes in the future. 
  





 CLINICAL ISOLATES 
ESBL-producing Escherichia coli isolated from urine samples from Otago patients by 
Southern Community Laboratories (SCL) between February 2015 and January 2016 
were included in the study. SCL routinely stores ESBL-producing isolates at -80oC when 
isolated for the first time; duplicate isolates are not routinely cryopreserved by SCL. 
Identity and resistance profile of the isolates were reconfirmed as follows to ensure no 
sampling error has occurred during storage procedure.  
 
 
As part of a previous study, the identity and resistance profile of isolates were 
reconfirmed to ensure no sampling error had occurred during the storage procedure 
(78). Species identification was confirmed by MALDI-TOF MS (Biotyper; Bruker 
Daltonics, Billerica, MA, USA) (78). Antibiotic resistance (ESBL production and 
multidrug resistance [MDR]) was confirmed using antibiotic disc diffusion tests 
according to EUCAST guidelines (78,116). The ESBL group (e.g. CTX-M group 1, group 9 
or TEM/SHV/OXA) of the isolates had previously been identified by PCR (78,117). 
Isolates were tested for 4 common MLST types (ST131, ST69, ST95 and ST73) by PCR 
(2,78). Following confirmation, isolates were cryopreserved in glycerol stocks (15% 
glycerol in LB broth) at -80oC. To begin, isolates were subcultured from glycerol stocks 
and grown/maintained on LB agar.  
 
 
 PLASMID STUDIES 
 Conjugation 
Plasmids encoding resistance to extended spectrum cephalosporins were isolated by 
transfer to an extended spectrum cephalosporin susceptible, sodium azide resistant 




recipient laboratory E. coli strain; E. coli J53, a K12 derived strain. An adapted filter 





The optimized method (run on all isolates) was as follows: 1 colony of either the donor 
(ESBL E. coli clinical isolates) or the recipient (sodium azide resistant  E. coli  J53) 
bacterial strains were inoculated to 10 mL LB broths and were incubated overnight at 
37oC , shaking at 200 rpm. The following morning recipient and donor bacteria were 
mixed in a 1:1 ratio (500 µL: 500 µL) in 1.5 mL Eppendorf tubes, vortexed for 10 s, and 
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Figure 2: Filter mating conjugation method 
 




Filter (Merck KGaA, Darmstadt, Germany) placed on plain LB agar as shown in Figure 2. 
For controls, 30 µL of E. coli J53 only or of the test isolate only were also pipetted onto 
membrane filters. Following overnight incubation at 37oC, filter papers with growth 
were vortexed in a sterile bijoux bottle containing 2 mL phosphate buffered saline (PBS). 
30 µL of this solution was spread onto a LB agar plate containing sodium azide 250 
mg/L and CTX 1.5 mg/L and incubated overnight (37oC). Resulting colonies were 
considered putative transconjugants, were purity plated, and tested by PCR for the ESBL 
gene that was present in the donor strain and for the IS5 sequence insertion in the 
orf264 gene that is only present in K12 derived laboratory strains (117,120). Glycerol 




The methodology was refined during the project. In some experiments the ratio of donor 
to recipient was varied from 1:1 to 1:9. Membrane filters with pore sizes of 0.22 µm and 
0.45 µm were compared in some experiments. 
 
 
 Agar dilution method to determine optimal concentrations of sodium 
azide and cefotaxime 
The ability of E. coli J53 and clinical isolates to grow at different concentrations of 
sodium azide and cefotaxime was determined by the agar dilution method (121). 
Sodium azide concentrations of 150 mg/L to 400 mg/L and cefotaxime concentrations of 
1.5 to 2 mg/L were assessed. All bacterial strains were suspended in PBS to an OD600 of 
1.0-1.2, equivalent to the absorbance observed for the isolates following the conjugation 
procedure, and 0.85 µL of this suspension was plated onto agar plates. Plates were 
incubated at 37oC overnight and then inspected for visible growth. 
 
 




 Derivation of sodium azide resistance 
To derive a strain of E. coli J53 with greater resistance to sodium azide, the strain was 
grown to confluence on LB agar supplemented with 150 mg/L sodium azide. A dense 
suspension was then made in PBS solution from a sweep of the plate. 50 µL of this 
suspension was then plated on to LB agar containing 200 mg/L or 300 mg/L of sodium 
azide (122). Colonies from the highest concentration sodium azide-supplemented plate 
yielding growth were regrown overnight on LB agar containing the same concentration 
of sodium azide. The above process was then repeated with increasing concentrations of 
sodium azide (in 25 mg/L increments) until growth was obtained on plates containing 
400 mg/L sodium azide.  
 
 
 PLASMID ISOLATION: MODIFIED ALKALINE LYSIS METHOD 
Plasmids were isolated from donor strains using a modified alkaline lysis method 
described by Herringa et al. which is suitable for large plasmids (123). Briefly, strains 
were grown in 10 mL LB broth overnight, 1.5 mL of which was centrifuged for 10 
minutes at 4000xg to pellet the bacteria, then resuspended in 100 µL resuspension 
buffer (50 mM glucose/10 mM EDTA/10 mM Tris-Cl, pH 8.0) by vortexing. 200 µL of 
lysis solution (0.2 M NaOH/1% sodium dodecyl sulfate [SDS]) was then added, mixed by 
inversion and incubated for 5 minutes at room temperature. To this 150 µL 7.5 M 
ammonium acetate and 150 µL chloroform was added, mixed by inversion and chilled 
on ice for 10 minutes and then centrifuged at 14,000xg for 10 minutes. The resulting 
supernatant was transferred to a new microfuge tube with 200 µL precipitation solution 
(30% polyethylene glycol 8000/1.5 M NaCl), mixed by inversion, chilled on ice 15 
minutes, then centrifuged at 14,000xg for 10 minutes to pellet DNA. The supernatant 
was removed and the DNA pellet resuspended in 50 µL UltraPure™ DEPC-treated water 
(Thermo Fisher Scientific) at 4oC overnight (123). The quality of plasmid DNA obtained 
was assessed by Nanodrop (Nanodrop one, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). OD 260/280 of around 1.8 and OD 260/230 of 2.0-2.2 were 
considered benchmarks for purity (124,125). 




 PREPARATION OF ELECTROCOMPETENT BACTERIA 
The ESBL carrying plasmids for any isolates that were unable to be conjugated using the 
filter mating method, were obtained using transformation. Initially electrocompetent E. 
coli ST18 cells were used but showed a low rate of successful transformation (3/6). 
Electrocompetent E. coli DH10B cells (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) may be a better host for large plasmids than E. coli ST18 so were 
used for the majority of experiments (126,127).The DH10B electrocompetent strain was 
prepared in-house as depicted in Figure 3 using the following protocol. SOB broth was 
prepared with 950 mL dH2O, 20 g BD Bacto™ Tryptone (Becton, Dickenson & Co., NJ, 
USA), 5 g BD Bacto™ Yeast Extract (Becton, Dickenson & Co., NJ, USA), 0.5 g NaCl, and 10 
mL of 250 mM KCl. Two 500 mL flasks of SOB broth were inoculated with 0.5 mL of an 
overnight culture and grown for 3 hours (or until an OD550 of 0.7 was reached) at 37oC 
200 rpm. Cells were then pelleted by centrifugation for 10 minutes at 7000 rpm, washed 
twice with an equal volume (to the original culture volume) of ice cold 10% glycerol, 
then once with half volume, then with 30 mL; Cells were pelleted by centrifugation at 
7000 rpm for 5 minutes between each wash step. After the final wash step the 
supernatant was removed and the cells were resuspended in 2 mL of 10% glycerol per 
litre of original culture. To finish, 40 µL aliquots were transferred into sterile 1.5 mL 
Eppendorf tubes and frozen at -80oC until use (127). 









One microliter of plasmid DNA, containing 40-80 ng DNA unless otherwise specified, 
was added to a chilled 1.5 mL Eppendorf tube. A 40 L aliquot of electrocompetent 
DH10B cells was defrosted for a few minutes on ice and then 20 L of DH10B cells were 
added to the Eppendorf containing DNA. Cells and DNA were then transferred to a 0.1 
cm electroporation cuvette, and electroporated at 1.8 kV, 200 ohm, 25 µF (standard E. 
coli bacterial settings) using the Gene Pulser Xcell Electroporation system (Bio-Rad 
Laboratories, Inc, Hercules, CA, USA) (128). Following electroporation, 960 µL of pre-




warmed LB was added to the cuvette containing electroporated cells, then transferred to 
sterile bijoux, which was incubated for 1 hr at 37oC shaking at 200rpm. Following 
incubation, 5 µL, 50 µL, and 500 µL were plated on to LB agar plates supplemented with 
cefotaxime (1 mg/L). Following overnight incubation at 37oC, single colonies were 
selected, and purity plates made. A negative control (DH10B only) was included in each 
electroporation run to ensure the DH10B cells did not grow on the LB agar 
supplemented with cefotaxime. A positive control plasmid (pUC19) was also run (grown 
on non-selective LB agar) to check the electrocompetence of the DH10B strain. The 
electrocompetent strain was also streaked on non-selective LB agar to check viability. 
The presence of the ESBL gene in putative transformants was confirmed by PCR as 
outlined above, with appropriate negative (DH10B and NTC) and positive controls 
(clinical isolate). Glycerol stocks (15% glycerol in LB broth) of the successful 
transformants were made and stored at -80oC. The electroporation method is 




Figure 4: Electroporation 
 




 CONFIRMATION OF SUCCESSFUL CONJUGATION OR 
TRANSFORMATION BY PCR 
Rapid DNA extraction was performed using the boiling method (117). Briefly, one colony 
was suspended in 100 µL of PCR-grade distilled water, heated at 95°C for 10 min, then 
centrifuged at 13,000xg for 10min and the supernatant collected. 
 
For ESBL gene presence confirmation, multiplex PCR assays were performed, and 
products identified by band size following gel electrophoresis according to procedure 
and primers described by Dallene et al (117). “Multiplex II” primer mastermix contained 
forward and reverse primers for amplification/detection of CTX-M groups 1, 2, and 9, 
“Multiplex I” for TEM, SHV and OXA-like, and “Singleplex 8/25” for CTX-M groups 8 and 
25 were used; the primers, product sizes, and references are provided in Table 1 (117). 
A positive control was used for the CTX-M group 9 primers (CTX-M-15 encoding ST131 
E. coli from ESR) but was not available for other targets. A no template control was 
included with each PCR run. The Robust Kapa2G Hotstart PCR kit was used (Kapa 
Biosystems, Wilmington, MA). Primer mastermix stocks were prepared at final 
concentrations of 0.2 µM each, except for CTXMGp2_FOR which was prepared at 0.1 µM 
as per the method of Dallene et al, using TE Buffer (Ambion, Austin, TX) (117). 
 
  




































































































































































































































































*Table 1 taken from Dallenne et al. (117). 
 




The mastermix for PCR reactions was prepared as outlined in Table 2. Each reaction 
included 1 µL of DNA template or, for the no template control (NTC), 1 µL of PCR-grade 
water (Invitrogen, NY, USA). ST131/CTX-M group 9 control strain was used as a positive 
control for Multiplex II. Amplification was carried out according to the KAPA2G Robust 
Hotstart operating procedure as follows: initial denaturation at 95°C for 3 min; 40 cycles 
of 95°C for 30 s, 60°C for 30 s and 72°C for 1 min; and a final elongation step at 72°C for 
1 min.  
 
 
Table 2: KAPA2G Robust Hotstart kit mastermix 
Component Volume per 25 µL reaction 
KAPA2G Buffer B 5 µL 
dNTP Mix 10mM 0.5 µL 
Primer Mastermix a 18.4 µL 
5 U/µL KAPA2G Robust Hotstart DNA 
polymerase 
0. 1 µL 
a Final primer concentrations as per Table 1 
 
PCR products were run on 2% agarose gel (Molecular grade agarose gel [Thermo Fisher 
Scientific, Waltham, Massachusetts, USA] and Bionic buffer [Sigma-Aldrich, St. Louis, MO, 
USA]), supplemented with 10 µL (to 100 mL agar) SYBR safe (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA), at 100 V for 1 hour. A 100-1000 bp ladder: GeneRuler 
100 bp DNA Ladder (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was used 
as products ranged from 100 bp-900 bp. The gel was visualized with an ultraviolet (UV) 
gel imager.  
 
 
PCR was also used to confirm that the putative transconjugants were the J53 strain of E. 
coli, which is derived from the laboratory K12 strain (120). The method described by 
Kuhnert et al targets the IS5 sequence insertion in the orf264 gene, which is present in 
K12 strains, as illustrated in Figure 5 (120). The primers and their targets are shown in 
Table 3 (120). PCR for K12 was performed using the KAPA2G Robust Hotstart kit, with 
the mastermix as above (Table 2). The following conditions were used: denaturation at 




95°C for 3 min; 40 cycles of 95°C for 30 s, 60°C for 30 s and 72°C for 1 min; and a final 
elongation step at 72°C for 1 min. The sodium azide-resistant strain E. coli J53 strain was 
used as a positive control and one of the clinical strains, and the group 9 E. coli from ESR 
were used as negative controls.  
 
 
Gel electrophoresis was performed with 1% agar (Seaplaque low melting point agarose: 
Lonza, Rockland, ME, USA + Bionic buffer Sigma-Aldrich, St. Louis, MO, USA), 
supplemented with 10 µL SYBR safe (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA), and 1 Kbp plus DNA Ladder (Invitrogen Life Technologies, Carlsbad, CA, USA). The 
gel was visualized with a UV gel imager. 
 
 
Table 3: K12 identification primers  
Primer Sequence Positions Reference Gene 
K12-R 5’-ATCCTGCGCACC AATCAACAA-3` 508 to 488 orf264 
K12-L 5’-TTCCCACGGACATGAAGACTACA-3` 21 to 43 
K12IS-L 5`-CGCGATGGAAGATGCTCTGTA-3` 293 to 313 IS5 
*Table 3 taken from Kuhnert et al. (121) 
Figure 5: K12 PCR primer locations. Arrows show locations of primers used for K12 
PCR, and boxes represent genes. orf264 (shaded box), which encodes rhamnose 
transferase, harbours an IS5 sequence in most K-12 strains specifying the rfb-50 
mutation. The K12-L primer is dependent on the complete gene orf264. K12IS-L primer 
is dependent on the 3’ end of orf264 and the presence of IS5; K12-R is the reverse 








  DNA SEQUENCING WITH MINION 
Plasmids from conjugants and transformants where extracted and sequenced using the 
MinION (Oxford Nanopore Technologies Ltd, Oxford, UK). 
   
 
 Preparing Input DNA 
Plasmids of the conjugates and transformants were isolated using the modified alkaline 
lysis method described above (123). Plasmid quantity and quality was assessed using 
the Nanodrop one (ThermoFisher Scientific, MA, USA). OD 260/280 of around 1.8 and 
OD 260/230 of 2.0-2.2 were considered benchmarks for purity. Plasmids were then 
cleaned using Agencourt AMPure XP beads (Beckman Coulter, High Wycombe, UK) and 
80% ethanol. Briefly, 54 µL (1.8x) of AMPure XP beads at room temperature were mixed 
with 30 µL plasmid DNA in a 1.5 mL Eppendorf tube, incubated for 5 minutes at room 
temperature, placed in magnetic rack (Figure 6), and allowed to clear (as beads are 
drawn to the magnet) (129). The supernatant was removed, then 200 µL of freshly 
prepared 80% ethanol was added to tube, incubated for 30 seconds, then removed; this 
wash step was repeated. The beads were air dried, removed from magnet, then 
resuspended in 40 µL of DEPC water and incubated for 5 minutes at room temperature 
to elute DNA. The tube was then placed on magnet again and clear supernatant 




Figure 6: Magnetic Separation Rack. Figure taken from reference (129). 
 





One microliter of cleaned plasmid DNA was diluted 1 in 10 with DEPC water to measure 
quantity and quality. The quality was assessed with 1 µL on the Nanodrop. The Qubit 
Fluorometer (Invitrogen) was used to accurately determine the DNA quantity following 
the manufacturer’s protocol. Briefly, 1 µL of diluted DNA was mixed with 199 µL 
working solution (prepared by adding 1 µL Qubit HS dsDNA reagent to 199 µL Qubit 
dsDNA HS buffer) and incubated for 3 minutes at room temperature. The two standards 
provided (prepared by adding 10 µL standard to 190 µL working solution, incubated for 
3 minutes at room temperature) were used to calibrate the Qubit before measurement. 
The remaining 8 µL of cleaned diluted DNA was run on 0.8% low melting point agarose 
gel at 70 V for 15-50 minutes to check for unwanted shearing.   
 
 
 DNA Library Preparation 
The DNA library was prepared using the Rapid Barcoding Sequencing kit (SQK-RBK004) 
(Oxford Nanopore Technologies Ltd, Oxford, UK) according to the protocol provided by 
the manufacturer. This kit comes with 12 barcodes; that is 12 specimens can be run per 
batch. Kit components (stored at -20oC) were thawed at room temperature and 
centrifuged briefly prior to use.  
 
 
DNA was diluted to 400 ng/7.5 µL in DEPC water in a volume of (at least) 10 µL. The 
concentration was checked using the Qubit Fluorometer (Invitrogen) using the 
procedure described above. Then 7.5 µL of this diluted DNA (containing 400 ng DNA) 
was combined with 2.5 µL of one of 12 specific barcoded fragmentation mixes (RB01-
RB12: one for each sample) in a 0.2 mL thin walled PCR tube and mixed by gently 
flicking the tube. The mixtures were incubated at 30oC for 1 minute then at 80oC for 1 
minute in a thermocycler, then transferred to ice to cool. The barcoded samples were 
then pooled at equal (1:1) ratio (10 µL each).   
 
 




As more than four samples were barcoded at a time, a clean-up procedure was carried 
out in order to increase throughput as recommended by the ONT protocol. Briefly, an 
equal volume of AMPure XP beads at room temperature was added to the pooled 
sample, mixed by flicking the tube, and incubated on a Hula mixer (Invitrogen) for 5 
minutes at room temperature. Then the sample was pulse spun and pelleted on a 
magnet, and the supernatant was removed. The beads were then washed twice with 200 
µL 80% ethanol as previously described. The pellet was then resuspended in 10 µL of 10 
mM Tris-HCl pH 8.0/50 mM NaCl, incubated for 2 minutes at room temperature, pelleted 
using the magnet, and the supernatant containing DNA transferred to a clean 1.5 mL 
Eppendorf DNA LoBind tube. 1 µL of rapid adaptor (RAP) was added to 10 µL of 
barcoded DNA, mixed by flicking the tube, and incubated at room temperature for 5 
minutes. The prepared library was then stored on ice until ready to load onto the 
MinION flow cell.  
 
 
DNA library preparation methodology was refined during the study. Samples were run 
in four batches. One batch of fresh plasmids that were never frozen following extraction 
was compared to a batch where plasmids were frozen between quality testing and 
running on the MinION. Batch 4 was run on a new flow cell.  
 
 
 Running the MinION 
MinION sequencing was performed using R9.4 (FLO-MIN106) flow cells (Figure 7) 
(130). Sequencing was run for 5 – 12 hours. Oxford Nanopore Technologies MinKNOW 
software (versions 0.45.2.6 - 2.34.3) was used to collect raw electronic signal data. 
 
 
The MinION was plugged in to the computer and the MinION graphic user interface 
(GUI) turned on. Quality control (QC) was run on the flow cell before each run. Buffer 
containing a QC DNA molecule is present in the flow cell on arrival (this buffer is also 
provided separately for storage). The MinKNOW software (0.45.2.6 - 2.34.3)  recognizes 
the distinctive signal of the QC DNA molecule, allowing it to validate the integrity of the 




nanopore array, and outputs the estimated number of available (good quality) channels 
in groups of four for the experiment (130).  
 
 
Sequencing buffer, loading beads, flush buffer, and flush tether reagents (provided in the 
kit) were thawed at room temperature, then placed on ice. Sequencing buffer and flush 
buffer were mixed by vortexing, flush tether was mixed by pipetting, then all were 




The MinION was then opened and the priming port on the flow cell was opened 
(clockwise). A small volume was drawn back from the port to remove any bubble by 
turning the wheel of a P1000 pipette (set at 200 µL) to show 220-230 µL, whereupon a 
small volume of buffer enters the pipette tip. After visually confirming that there was 
continuous buffer from the priming port across the sensor array, the flow cell priming 
mix was prepared by mixing 30 L of thawed and mixed Flush tether with thawed and 
mixed flush buffer. Then 800 µL of the priming mix was loaded into the flow cell via the 
priming port and left for 5 minutes. 
   






Figure 7: Parts of the MinION flowcell. Figure adapted from reference (130) 
 
 
The sample loading library was then prepared by adding 34 µL Sequencing Buffer (SQB) 
to an Eppendorf tube, followed by 4.5 µL Nuclease-free water. The Loading Beads (LB) 
were mixed by pipetting up and down then 25.5 µL was added to the mixture. Finally, 11 
µL of the prepared DNA library was added to the mixture. The sample port cover was 
then opened and a further 200 µL of priming mix was added to the priming port (Figure 
7). The sample library was mixed by flicking the tube prior to loading. Then the 75 µL 
sample library was added to the sample port dropwise without touching the port. 
Sample and priming ports, and MinION lid were closed, and the sequencing run was 
begun using the MinKNOW software (version 0.45.2.6 - 2.34.3). 
 
 
During the run, several parameters were checked on the MinKNOW software (version 
0.45.2.6 - 2.34.3) including the number of active pores (ideally within 10-15% similarity 
to the active pores called during QC), heatsink temperature (ideally 34oC), the read 
length histogram, and pore occupancy (ideally 70% of all active pores in the first 30 




minutes). The run time was selected to be 5 hours, and live-base calling was used for the 
first batch. For the two subsequent batches the run time was increased to 12hrs in order 
to increase output and live-base calling was not used (due to the increased run time to 
prevent loss of data from any connection issues). The last batch was run for 5 hours but 
live base calling was not utilized. EPI2ME software (version 2.52- 2.58) was used to 
analyse the MinION data. The flowcell was washed between each use by adding 150 µL 
of solution A followed by 150 µL of solution B. 500 µL of storage buffer was added 
before storing the flowcell. 
 
 
 ILLUMINA  NEXTSEQ WHOLE GENOME SEQUENCING DATA 
ANALYSIS 
All 66 isolates underwent whole genome sequencing (WGS) on an Illumina NextSeq 
instrument (San Diego, CA) at the Microbiological Diagnostic Unit Public Health 
Laboratory (MDU PHL), University of Melbourne. DNA extraction and library 
preparation were performed at the MDU PHL. The resulting data was analysed in this 
project. The Nullarbor (version 1.20) bioinformatic pipeline was used to determine the 
sequence type, the resistance genes present, and the phylogenetic relationship of 
isolates from the WGS data (131). In the Nullarbor pipeline, Trimmomatic (version 0.27) 
was used to clean the reads, then de novo assembly was conducted with SPAdes (version 
3.10.1) (131,132,110). Species identity was detected with kraken (version 0.10.5-beta). 
The sequence type was determined by in silico MLST with mlst (2.8), which 
automatically detects the appropriate scheme (131). The resistance genes were defined 
with Abricate (version 0.4) (131,133). Variants were identified with Snippy (version 3.2-
dev) (134).  FastTree, along with Snippy (version 3.2-dev) was used to determine the 
phylogenetic relationship of isolates based on core genome single nucleotide 
polymorphisms (SNPs) using the Escherichia coli ST131 strain EC958 complete genome 
(Genbank: HG941718.1) as the reference genome (134,135). Lastly, the accessory 
genome was compared with Roary (version 3.11.3) (136). Nullarbor outputs a .html 
format report that summarizes the quality of reads, species identification, MLST, and 




resistance profile of each isolate as well as pan genome and core genome phylogeny 
trees, with core SNP distances and density.  
 
 MINION DATA ANALYSIS 
The following describes the post analysis data processing of the MinION reads, from 
quality control to basecalling the MinION reads to the hybrid assembly of MinION reads 
and Illumina reads. Figure 8 summarizes the finished pipeline (137). 
 
 Basecalling and Demultiplexing 
The first batch was base-called in real-time using the MinKNOW software (versions 
0.45.2.6 - 2.34.3) (Oxford Nanopore Technologies, Oxford, UK), which produces fastq 
files. Subsequent batches were not live-base-called: output was in the format fast5. 
Albacore (version 2.3.0) (Oxford Nanopore Technologies, Oxford, UK) was used to base-
call these fast5 files, converting them to fastq (see Appendix A Fig 1). Porechop (version 
0.2.3) was used to demultiplex and to remove adaptor sequences; a shell program (See 
Appendix A Fig 2) was written to partially automate the process (107).  
 
 
 Quality Assessment 
EPI2me (version 2.52- 2.58) (Oxford Nanopore Technologies, Oxford, UK) was used to 
assess the quality of each sample. EPI2me provided mean and median read length, read 
number, and read quality for each barcode. These parameters were compared between 
each batch.   
 




 Hybrid Assembly (Data Analysis) 
Hybrid assembly using MinION reads as scaffolds and Illumina reads for error correction 
was used to construct complete plasmid sequences. Methodology was refined during the 
study. Three program options were trialled and compared using a subset of isolates. 
First Miniasm/Minimap (version 0.2) (a long-read only assembler) followed by SPAdes 
(version 3.11.1) (used as a hybrid read assembler) (see Appendix A Fig 3) (110,138). 
Second, the ‘–plasmid’ option of SPAdes (version 3.11.1) (see Appendix A Fig 3). Third, 
bowtie2 (version 2.3.4.1) in combination with the Unicycler pipeline (version 0.4.6) (See 
Appendix A Fig 4-Fig 6) (139,140).  
 
 
Bowtie2/Unicycler was concluded to be the best method and was used in the final 
version of the hybrid assembly pipeline (139,140). Bowtie2 (version 2.3.4.1) is a tool 
that aligns reads to reference genomes. Unicycler is an assembler specialized for 
combining Illlumina and MinION data (139). Unicycler (version 0.4.6) uses a specialized 
algorithm involving the use of SPAdes (version 3.11.1), Miniasm (version 0.2), Racon ( 
version 1.2.1), BLAST+ (version 2.2.31), Pilon (version 1.22), Java (version 1.8.0_151), 
bowtie2 (version 2.3.4.1), and samtools (version 1.4.1) (139). Unicycler (version 
0.4.6) was used to perform hybrid assembly of all the plasmids.   
 
 
 bowtie2 filtering  
The whole genome of each isolate was sequenced on the Illumina. However, only the 
plasmids encoding the ESBL gene that were able to be isolated were sequenced with the 
MinION. As this difference in data may cause difficulties or errors during assembly, 
bowtie2 filtering (version 2.3.4.1) was used to prefilter the Illumina reads to include only 
those that match the relevant plasmid as sequenced by the MinION (140). Any hybrid 
assembly that did not yield a complete plasmid with Unicycler alone was repeated with 
bowtie2 filtering.  
 
 




As bowtie2 requires fasta (.fa) files to build reference a database, Miniasm (version 0.2) 
was used to generate a long read only assembly (from the MinION reads) (Appendix A 
Fig 4) (138). As long read only assembly has a higher error rate, and filtering Illumina 
reads on this assembly may filter out relevant Illumina sequences, affecting the accuracy 
of downstream analyses, sed was used instead of Miniasm to convert the long read fastq 
files to fasta files of any plasmids that were incomplete with Miniasm (Appendix A Fig 4). 
 
  
The bowtie2 build function (version 2.3.4.1) was then used to make an index from the 
resulting output file (from Miniasm or sed). Then bowtie2 (version 2.3.4.1) was run to 
give an output of paired Illumina reads (forward and reverse files) that matched to the 
index. The ‘--very-sensitive local’ pre-set was used to account for the higher error rate in 
the MinION reads. The paired output files of bowtie2 can be used just as unfiltered 
paired Illumina reads as input for Unicycler. 
 
 
 Analyses on Completed Plasmids 
Following successful plasmid assembly, the resulting graph (.fastg output) was viewed 
on Bandage (version 0.8.1), which facilitates the manual curation of assemblies based on 
coverage and connections between contigs, to determine the location and multiplicity of 
resistance genes and to allow manual annotation (141). Plasmids were typed in silico 
using PlasmidFinder (version 1.3-2.0) and pMLST (version 1.4) (the full sequence of the 
circularized plasmids in .fa format were used as input) (142). ISfinder (version 2.2.31), 
was used to identify insertion sequence, which were then manually annotated on the 
Bandage graph (143). NCBI blast (version 2.8.0), EPI2me antimicrobial resistance 
application (version 2.2.14), ResFinder (version 3.1), and CARD antimicrobial resistance 








A sunburst chart of the MinION data was created to visualize the diversity of the isolates. 
The pan genome tree Nullarbor output was labelled with the MinION data (and the 




Figure 8: Bioinformatic pipeline graph  
 




 STATISTICAL ANALYSIS 
Results were tabulated and analysed statistically. The χ 2 test and post hoc binomial test 
and sign test was used for statistical analysis. A two-tailed p < 0.05 was considered 
significant. All analyses were performed using the statistical software SPSS (build 
1.0.0.1246; SPSS Inc., Chicago, IL, USA) and Excel Analyse-it for Microsoft Excel (version 
2.20, Analyse-it Software, Ltd. https://analyse-it.com/; 2009). 
   





 CLINICAL ISOLATES 
There were 140 ESBL E. coli isolated by SCL from urine samples from Otago (from both 
hospital and community patients) between February 2015 and January 2016 (inclusive). 
58 of these were duplicates, 10 were never stored, and 3 were missing from storage. Of 
the 69 non-duplicate ESBL E. coli urinary isolates collected, 66 were confirmed to be 
ESBL E. coli by MALDI-ToF MS and by susceptibility testing (78). Of the 3 isolates that 
were not ESBL E. coli, 2 were found to be AmpC producers, rather than ESBL-producers, 
and 1 was cefpodoxime susceptible and not an ESBL (78). This may reflect sampling 
error during storage in the presence of a double population of ESBL and non-ESBL-
producing bacteria. Most isolates (75.7%, n=50) were of community-origin. 
 
 
 WHOLE GENOME SEQUENCING: ILLUMINA RESULTS 
Overall sequence quality was flagged as acceptable in all but one isolate. The number of 
reads ranged from 1,371,106 to 6,021,814, with an average read length of 148-149 bp, 
and average depth of coverage of 75-172 fold (excluding the low-quality isolate which 
had a depth of 39 fold). All isolates had a Phred score of 33; a Phred score of greater than 
30 has an incorrect base call probability of 1 in 1000 (Supplementary Data, Appendix B). 
 
 
 Illumina Species Identification 
K-mer analysis against the kraken database confirmed the identity of all isolates as E. 
coli, with the first match for all isolates being E. coli, at 33.24% to 82.23% identification, 
and the second match for all isolates being <8.28%. The second match was unclassified 
in 62/66 (94%) cases, the other four being S. sonnei, K. pneumoniae, and (two) S. 




enterica. Even though the Nullarbor pipeline flagged the quality of reads for use in 
species identification to be low (<80%) in all but 13 of the isolates, the gap between the 
first and second match (most of which were ‘unclassified) was large in all isolates. The 
median identity classification percentage for the first match was 72.69%. There were 8 
isolates with identity classification percentage of less than 50% (33.24%-46.95%). 
These all had low quality scores as assessed by Nullarbor. There were 14 other isolates 
with low quality scores with identity classification percentage of 50.85-63.99% 
(Supplementary Data, Appendix B). 
 
 
 SNP Phylogeny 
Using E. coli ST131 (HG941718.1) as the reference genome, 6 -7 clusters were observed 
in the core genome phylogeny tree (Figure 9) (Supplementary Data, Appendix B).  
Several smaller clusters (9-10) were evident in the pan genome phylogeny tree (Figure 
10) (Supplementary Data, Appendix B). Several clusters which are separate in the pan 
genome tree appear to be closely related in the core genome tree. For example, the large 
cluster of 21 isolates (closely related to the reference genome) in the core genome tree, 
is separated into 3 disparate clusters in the pan-genome tree - one sub-group of 11 
isolates (isolate 68, 69, 15, 78, 12, 11, 82, 27, 44, 21, and 20), another sub-group of 2 
(isolates 36 and 58) and a further subgroup of 7 (isolates 8, 76, 85, 60, 73, 35, 40). In the 
other instance, a large cluster in the core genome (consisting of isolates 67, 54, 79, 66, 
75, 29, 38, 19, 26, 62, 39, 41, 45, and 72) appears as three separate sub-groups in the 
pan genome tree: one group of 6 isolates (isolates 67, 54, 79, 66, 75, and 71), another 
group of two isolates (isolates 29 and 38) and the remainder forming a group of 7. 
Isolate 10 is an example of where the pan genome tree indicating a single isolate with a 
differing accessory genome to those in the same cluster in the core genome tree. 






Figure 9: Core SNP phylogeny. Produced by FastTree (version 2.1.9 Double precision 
[No SSE3]) with SNP from Snippy-core (version 3.2-dev) (in the Nullarbor pipeline) 
using a reference genome of ST131 ESBL E. coli (Genbank: HG941718.1). Graph 
generated using iTOL online (version 3.0) reference (149) 
 





Figure 10: Pangenome SNP phylogeny. Produced by FastTree (version 2.1.9 Double 
precision [No SSE3]) and Roary (version 3.11.3) (in the Nullarbor pipeline). Graph 
generated using iTOL online (version 3.0) reference (149) 
 





MLST was performed by mlst (2.8) using the Achtman E. coli scheme, which includes 
seven conserved housekeeping genes: adk, fumC, gyrB, icd, mdh, purA and recA 
(Supplementary Data, Appendix B) (131,150).  There were 23 different sequence types 
(ST) identified. ST131 was the most common ST (27/66, 40.9%) followed by (in 
descending order) ST38 (7/66, 10.6%), ST405 (5/66, 7.6%), ST636 (4/66, 6.1%), 
ST648(3/66, 4.5%), ST127 (2/66, 3.0%), and one each of 15 different STs were found 
(ST10, ST12, ST14, ST69, ST95, ST101, ST162, ST297, ST393, ST410, ST448, ST457, 
ST744, ST1193, ST3036, and ST4204). The sequence type of 2 (3.0%) isolates was 
unable to be determined; the Nullarbor report had flagged these sequence reads as low 
quality (Supplementary Data, Appendix B). These isolates had previously been identified 











Figure 11: MLST of ESBL E. coli isolates. This figure includes the ST131 isolate and the 
ST69 isolate that were previously identified by PCR (78) with the MLST data gleaned 




 ESBL Genes and other -lactamase genes 
The β-lactamase genes for CTX-M-27, CTX-M-14, CTX-M-15, CTX-M-55, TEM-1B, TEM-
1A, SHV-12, OXA-1 and OXA-9, were identified alone and in combination (Table 4) 
(Supplementary Data, Appendix B). In addition, there was one CMY-2 AmpC resistance 
gene found in conjunction with CTX-M-15 and TEM-1B. Of note, neither of the OXA 
variants identified, nor TEM-1 are known to have an ESBL phenotype (144-146). SHV-12 
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The majority of isolates (36/66, 54.5%) contained TEM, SHV and/or OXA genes 
according to WGS. However most (27/36, 75%) were in combination with CTX-M genes 
(which are likely to be solely responsible for the ESBL phenotype), with only 9 being 
found alone. Most of the OXA genes were OXA-1 (10/12, 83.3%), with only two OXA-9 
(2/12, 16.7%). These two OXA-9 were the only OXA genes found in combination with 
TEM1B and SHV, and not in combination with a CTX-M gene. It should also be noted that 
no SHV genes were found in combination with CTX-M genes, with SHV found in most of 
the isolates not containing CTX-M genes (8/9, 88.9%). Instead a CTX-M/TEM-1B 
combination was the most common (17/27, 63.0%), with only 6 (22.2%) containing the 
CTX-M/OXA combination, and a further 4 (14.8%) with a CTX-M/OXA/TEM1B 
combination. These combinations were found across all CTX-M groups. CTX-M-14 and 
CTX-M-55 were found only in combination with TEM1B, while both OXA and TEM1B 
appeared in CTX-M-27 and CTX-M-15 carrying isolates. CTX-M-27 was notable as the 
only CTX-M gene type where the majority did not occur in combination with TEM1B or 
OXA genes; 14/18 (77.8%) of CTX-M-27 isolates carried CTX-M-27 only).  
 
 
There were more group 9 CTX-M ESBL genes (35/66, 53.0%) than group 1 CTX-M ESBL 
genes (20/66, 30.3%), though this difference was not significant (p >0.05). While the 
group 9 CTX-M genes were roughly evenly split between CTX-M-14 (17/35, 48.6%) and 
CTX-M-27 (18/35, 51.4%), the majority of group 1 CTX-M genes were CTX-M-15 (15/20, 
75%) with only 7 (35%) CTX-M-55 genes. In two isolates (3.0%) CTX-M-14 genes were 
found in conjunction with CTX-M-55; these isolates are considered separately for clarity. 
Though CTX-M-14 genes were the most common CTX-M gene there was no significant 










Table 4: Beta lactamase gene proportions 
Βeta-lactamase encoding genes Number Percentage (%) 
Total CTX-M 57 86.4 
                                                  CTX-M-14/55 2 3.0 
           Total Group 9 35 53.0 
                      Total CTX-M-14 17 25.7 
                                                  CTX-M-14 7 10.6 
                                                  CTX-M-14/TEM-1B 10 15.2 
                       Total CTX-M-27 18 27.3 
                                                  CTX-M-27 14 21.2 
                                                  CTX-M-27/TEM-1B 2 3.0 
                                                  CTX-M-27/OXA-1 2 3.0 
             Total Group 1 20 30.3 
                       Total CTX-M-15 15 21.2 
                                                  CTX-M-15 5 7.6 
                                                  CTX-M-15/OXA-1 4 6.1 
                                                  CTX-M-15/OXA-1/TEM-1B 4 6.1 
                                                  CTX-M-15/TEM-1B 2 3.0 
                       Total CTX-M-55 5 7.6 
                                                  CTX-M-55 2 3.0 
                                                  CTX-M-55/TEM-1B 3 4.5 
Total SHV/TEM/OXA only 9 13.6 
                                                 TEM1B 1 1.5 
                                                 SHV-12 1 1.5 
                                                 SHV-12/TEM-1B 5 7.6 
                                                 SHV-12/TEM-1A/OXA-9 2 3.0 
 
 
 Relationships between ESBL genes and MLST 
Figure 12 shows the MLST types of the isolates carrying different ESBL genes. In 
accordance with the high number of sequence types identified in this study, there was 
high diversity of MLST types observed carrying  each ESBL gene, with all CTX-M gene 
types being found in isolates of different sequence types. All isolates encoding CTX-M-55 




alone were of different sequence types, namely ST38, ST95, ST131, ST1193, and ST4204, 
though the two CTX-M-55/CTX-M-14 encoding isolates were both ST69. However, 
associations between MLST and ESBL genes were also observed. While ST131 isolates 
carried all types of CTX-M genes, ST131 was the most frequent MLST carrying CTX-M-15 
(7/15, 46.7%) and CTX-M-14 (6/17, 35.3%). ST131 isolates also represented the 
majority of isolates carrying CTX-M-27 (72.2%, 13/18), and a statistically significant 
association of ST131 with CTX-M-27 was observed (p <0.01) by χ2 test. There were only 
3 other MLST types that carried CTX-M-27, compared to 6 and 7 respectively for CTX-M-
14 and CTX-M-15. The numbers of other STs and CTX-M types were too small for  
statistical analysis. Nevertheless, it is worth noting that most (4/5, 80%) SHV/TEM 
producing isolates were ST636, and the isolates with CTX-M-14 and CTX-M-55 in 










Figure 12: MLST and beta-lactamase gene relationship 
 
 
 Other resistance genes 
 
The resistance genes for other antibiotic classes are illustrated in Figure 13. Genes 
encoding resistance to aminoglycosides, trimethoprim, sulphonamides, tetracyclines, 
macrolides, chloramphenicol, and quinolones were found. Notably, no complete colistin 
resistance genes were seen, though a partial MCR-1 gene was found in one isolate. Only 












































































Of the 66 isolates, resistance genes against tetracyclines were found in 39 (59.0%), 
sulfonamides in 40 (60.6%), macrolides in 36 (54.5%), trimethoprim in 41 (62.1%), and 
aminoglycoside only in 38 (74.2%). Less commonly identified resistance genes included 
those to both quinolones and aminoglycosides in 11 (16.7%), quinolones only in 3 
(6.1%), chloramphenicol in 14 (21.2%), fosfomycin in 3 (4.5%), and lincosamides in 1 
(1.5%). Considering aminoglycoside modifying enzyme encoding genes individually, 29 
(43.9%) isolates carried genes encoding resistance to gentamicin, 38 (57.6%) to 
spectinomycin and/or streptomycin, and 4 (6%) to kanamycin and neomycin. strA and 
strB streptomycin and spectomycin resistance genes always occurred together. 
Considering quinolone resistance, 14 (21.2%) isolates carried resistance genes to 
ciprofloxacin. Most (10/14, 71.4%) were aac(6′)-Ib-cr genes, with the remainder being 
qnr genes split evenly between qnrS and qnrA. Considering trimethoprim resistance, the 
dfrA17 gene was the most common resistance determinant (27/41, 65.9%), followed by 
dfrA1 (7/41, 17.1%) and dfrA12 (6/41, 14.6%).  
 
Genes encoding resistance to 3 or more classes of antibiotics, were found in 42/66 
(63.6%) of isolates (151). This phenomena was found far more commonly in CTX-M type 
ESBL (39/57, 68.4%) than TEM-1B/OXA-9/SHV-12 carrying ESBLs (3/9, 33.3%) 
(p<0.05%). The incidence of this phenomena did not differ greatly between different 
CTX-M types (CTX-M-14, 11/17 (64.7%); CTX-M-15, 10/15 (66.7%); CTX-M-27, 14/18 
(77.8%); CTX-M-55, 2/5 (40%); CTX-M-14/55, 2/2 (100%). Of note, 8/10 (80%) 
aac(6′)-Ib-cr encoding isolates also encoded CTX-M-15. 
 
 
 Comparison with Phenotypic Resistance 
Genotypic resistance was compared with phenotypic resistance, as determined by disc 
diffusion according to EUCAST guidelines in a previous study (78). Of the 14 isolates 
with genotypic quinolone resistance, all except one (encoding the qnrS gene) showed 
phenotypic quinolone resistance to ciprofloxacin. Phenotypic resistance to ciprofloxacin 
was seen in 51/66 (77.3%) isolates, 38 (74.5%) of which had no detectable quinolone 
resistance gene; mutations in the quinolone resistance determining region (QRDR) were 
not assessed. Of 29 isolates with genotypic gentamicin resistance, 6 (21%) were 




phenotypically susceptible to gentamicin. On the other hand, 1 isolate showed 
phenotypic resistance and 1 isolate intermediate susceptibility to gentamicin despite no 
corresponding resistance gene. Out of 45 isolates encoding a sul or dfrA resistance gene, 
8 (17.8%) were susceptible to co-trimoxazole. On the other hand, 2/39 (5%) showed 
resistance to co-trimoxazole despite no sul or dfrA genes being present. Data on 











Figure 13: Distribution of non--lactam resistance genes among ESBL-producing E. 




















































































































































































































































































































Key: spectinomycin (SPT); streptomycin (STR); gentamicin (GEN); ciprofloxacin (CIP); kanamycin (KAN); neomycin (NEO); clindamycin (CLI); 
fosfomycin (FOF); chloramphenicol (CHL) 
*= Gentamicin, tobramycin and plazomicin 




 ISOLATION OF ESBL GENE-ENCODING PLASMIDS 
ESBL encoding plasmids were able to be isolated from 45 of 66 (68%) ESBL E. coli 
isolates. Of these, 33 (73.3%) were isolated by conjugation with the sodium azide 
resistant E. coli J53 strain. Figure 14 shows an image of gel electrophoresis of putative 
transconjugants following K12-specific PCR to confirm the strain was J53, with Figure 
15 showing the corresponding PCR products of multiplex II to confirm the presence of 
the ESBL gene from the donor strain in putative transconjugants (117,120). The 
remainder (12/45, 26.7%) were isolated by transformation of plasmid preparations 
from the clinical isolates into electrocompetent DH10B (10 isolates) or ST18 (2 isolates) 
E. coli strains. The presence of the ESBL gene from the donor strain in putative 
transformants was confirmed by PCR (Figure 16) (117).  
 






Figure 14: K12 confirmation of putative transconjugants (conjugation). Gel 
electrophoresis of PCR products of  putative transconjugants to confirm the success of 
conjugation by the presence of K12 specific band  L: 1Kb plus ladder : 100bp-12000bp  
(with 1000bp marked); PC: positive control: J53 strain with K12 specific band at  969 bp; 
NC: negative control ESBL E. coli clinical isolate- the donor isolate for the putative 
transconjugant in lane 1; NTC: no template negative control (DEPC water); 1-3: successful 
transconjugants with K12 specific band at 969 bp-  conjugation has occurred; 4: 
unsuccessful putative transconjugant with no band, indicating failure of conjugation. 





Figure 15: Multiplex II ESBL gene confirmation in putative transconjugants (conjugation). 
Gel electrophoresis of PCR products of multiplex II on putative transconjugants to confirm 
the presence of ESBL gene L: 100-1000 bp ladder (with 500 bp marked); 1 putative 
transconjugate with no band indicating that it is negative for CTX-M groups 1, 2, and 9 and 
that conjugation has failed;  2: successful transconjugate with band at  688 bp, positive for 
CTX-M group 1, indicating successful conjugation; 3, 4: successful transconjugates with band 
at 561 bp, positive for  CTX-M group 9, indicating successful conjugation; NC: negative 
control J53 strain; PC: positive control CTX-M group 1 ST131 from ESR with band at 688 bp; 



















 Optimization of Conjugation Method 
Firstly, the optimal concentration of sodium azide and cefotaxime to use in the selective 
agar were determined by the agar dilution method. E. coli J53 failed to grow at a 
cefotaxime concentration of 1.5 mg/L but was able to grow at sodium azide 
concentrations of 150 mg/L to 175 mg/L within 24 hours; diminished growth was seen 
up to 275 mg/L after 48 hours incubation. All of the clinical isolates grew at a cefotaxime 
concentration of 1.5 mg/L. While most clinical strains failed to grow on sodium azide, 
one isolate grew at 200 mg/L. Therefore, a more resistant strain of E. coli J53 was 
Figure 16: ESBL gene confirmation in putative transformants (electroporation). Gel 
electrophoresis of PCR products of multiplex II  putative transformants to confirm  the 
success of electroporation by the presence of ESBL gene specific PCR products L: 100-
1000bp ladder (500bp marked); A, C: successful transformant  with CTX-M group 9 specific 
band at 561bp - successful transformation; B: successful transformant with  CTX-M group 
1specific  band at 688bp- successful transformation; J: putative transformant with multiplex 
I non specific laddering failed transformation  NC1: negative control DH10B multiplex II; 
NC2: Negative control DH10B multiplex  I; PC: positive control CTX-M group 1 ST131 from 
ESR 688bp 




derived. This allowed a sodium azide concentration of 250 mg/L to be used for the 
conjugation experiments. 
 
Secondly, the optimum ratio of donor to recipient strains for conjugation was 
determined. Ratios of 1:1, 1:2, 1:3 and 1:9 were assessed using a representative 
selection of six isolates. The only transconjugant elucidated (as confirmed by PCR) in 
this batch was from the 1:1 ratio. The optimum pore size of the Millipore membrane 
filter was determined by comparing 0.22 µm and 0.45 µm with a selection of 5 isolates 
on each. One isolate was able to be transferred with 0.45 µm that was negative with 0.22 
µm. Five further test isolates run with 0.45 µm were all successful.  
 
 Optimization of Electroporation Method 
Nanodrop spectrophotometer purity assessment of extracted plasmid DNA found 
A260/280 values ranged from 1.92- 2.15, and the A260/230 values ranged from 1.23-
2.15 with a DNA yield ranging from 300-1300 ng/µL.  
 
To determine the optimal plasmid concentration for electroporation, plasmids from 6 
isolates were run at neat concentration (600-1300 ng/µL), 1 in 20 dilution, and 1 in 40 
dilution. The optimum range was found to be between 40-70 ng/µL, with efficiency rate 
dropping either side (lower at 15-30 ng/µL and at neat concentration). The optimum 
electrocompetent cell volume was determined between 20 µL (~4x109 cells) and 40 µL 
(~8x109 cells). The optimum electrocompetent cell volume was 40 µL (~8x109 cells). 
 
 
 MINION SEQUENCING 
 MinION Quality Control 
Nanodrop spectrophotometer purity assessment of extracted plasmid DNA found 
A260/280 values ranged from 2.08- 2.13 (before AMPureXP clean-up =2.14-2.18), and 




the A260/230 values ranged from 2.48-2.52 (before AMPureXP clean-up =2.24-2.34) 
with a DNA yield ranging from 300-1300 ng/µL. Low percent agarose gel 
electrophoresis analysis of input DNA showed high molecular weight DNA and no 
degradation or shearing was detected.  
 
 
The EPI2me quality analysis of the reads of all four MinION runs are summarized in 
Table 5. Run 1 and run 4 had the best quality scores. Run 4 had the longest read length, 
highest read number and highest yield average, though the quality score was lower than 
run 1. Run 4 used a new flow cell and run 1 used a flow cell that had only been used once 
previously. Freshly isolated plasmid was used in run 2 but this did not improve the 
quality score; though the read length average improved slightly, the read length mode 
was significantly lower. This compared to run 1 and run 4 where plasmids were stored 
between isolation, quality testing and analysis (2 days). Run 3 had the lowest quality 
score, read length, read number and yield. Run 3 plasmids were stored at -20oC for 3 
weeks prior to analysis. 
 
 
Table 5: EPI2me quality analysis of MinION reads 
 
Run 1 Run 2 Run 3  Run 4 
Read length average (bp) 12190 13045 10304 14070 
Read length mode (bp) 4850 2791 1233 4416 
Quality score average 11.53 9.705 9.5375 10.4775 
Quality score mode 12.75 9.705 10.042 10.96 
Read number average 1261 6089 647 2595 
Read number median 1188 4326 561 2062 
Yield average (Mbp) 20 50.94 6.86 37.11 
Run duration (h) 5 12 12 6 
Plasmid storage time 2 days 0 days 3 weeks 2 days 




 Hybrid Assembly 
Different hybrid assembly methods, namely, Miniasm/SPAdes, Miniasm/plasmid SPAdes, 
and Unicycler were trialed on three isolates. The outputs for one example isolate is 
shown in Figure 17. The Illumina only assembly with SPAdes resulted in a fragmentated 
assembly with many divergent nodes where short read sequences failed to fully resolve 
the genome and any plasmids (Figure 17A and 17B); this illustrates the deficiency of 
short reads in resolving assembly continuity. A hybrid assembly using Miniasm to 
assemble long reads followed by SPAdes for hybrid assembly with short reads was 
assessed with a subset of three isolates; it showed a similar fragmented appearance to 
assembly of Illumina data alone (Figure 17C). The ESBL genes were located on small 
nodes with divergent paths; where small circularized plasmids were produced, they did 
not carry ESBL genes. While using the ‘—plasmid’ option in SPAdes during hybrid 
assembly resulted in less fragmented assemblies, complete circularized plasmids 
carrying the ESBL gene in question were not obtained in any of the tested samples 
(Figure 17D). With the use of Unicycler complete plasmids carrying ESBL genes were 
obtained, though a highly fragmented assembly of other sequences (such as 
chromosome reads) was also present (Figure 16E). Prefiltering short reads with bowtie2 
removed these unwanted assemblies and resulted in assemblies of only the desired 
complete circularized plasmids (Figure 17F). 
 
 
We were able obtain complete circularized plasmids from 25 isolates without using 
bowtie2 filtering. The remaining 20 unresolved plasmids and an additional 5 already 
completed plasmids were run with the bowtie2 prefilters. Using bowtie2 prefilters 
resulted in a complete plasmid in 4 out of 5 (80%) plasmids that had been completed 
without the filter, with the remaining 1 giving a linear plasmid. Sixteen of the 20 (80%) 
previously unresolved plasmids were able to be completed using the bowtie2 prefilter. 
Only one plasmid that was unable to be completed with Miniasm was able to be 
completed with sed, however plasmid type was unable to be identified.   
 
 
Overall, we were able to obtain a complete circularized plasmid assembly in 41/45 
isolates using the constructed pipeline. These four non-circularized plasmids were from 




different MinION runs, therefore variation in sequence quality between runs was not the 
cause.  However, sufficient information could still be obtained from 3 of 4 of these non-
circularized plasmids  to characterize the insertion sequences around the ESBL gene and 
plasmid type. Conversely, plasmid type was unable to be identified (with PlasmidFinder) 
in 3 other isolates (from MinION runs 1 and 2) despite completed, circularized plasmids 


















a)Illumina contigs b)SPAdes- illumina only
c)Miniasm/SPAdes d)Miniasm/plasmid SPAdes
f)bowtie2/Unicycler 
e)Unicycler (ESBL gene 
carrying  plasmid circled) 
Figure 17: Assembly of one test isolate with different tools. The outputs of different tools 
used for hybrid assembly of one test isolate a) Illumina contigs from Nullarbor, short read 
length with CTX-M-27 on a 1767bp node b) Illumina only SPAdes assembly with CTX-M-27 on 
a 1767bp node in a fragmented assembly c) Miniasm/SPAdes hybrid assembly with CTX-M-27 
on a 1667bp node in a fragmented assembly d) plasmidSPAdes with no blast hits for CTX-M-
27 e) Unicycler output with CTX-M-27 on 105081bp plasmid (circled), in addition to branching 
assembly and another circular plasmid with no ESBL gene f) bowtie2 followed by Unicycler 
with a complete circularized 105081bp plasmid carrying CTX-M-27, and no other fragmented 
sequences 




 Beta-Lactamase Gene Type of Isolated Plasmids 
Of the 9 isolates which contained only one or more of TEM/SHV/OXA, a plasmid was 
able to be isolated from 6 (66.7%). Of 57 CTX-M encoding isolates, 39 (68.4%) ESBL-
encoding plasmids were able to be isolated. While an ESBL-encoding plasmid could be 
isolated from most CTX-M-27 encoding isolates (16/18, 88.9%), it was only possible in 
6/17 (42%) CTX-M-14 encoding isolates. Of the isolates encoding a group 1 CTX-M, a 
plasmid could be isolated from 9/15 (60%) CTX-M-15 encoding and 4/5 (80%) CTX-M-




The ESBL genes encoded by the 45 plasmids that were able to be transferred are shown 
in Table 6. Whole genome sequencing identified all β-lactamase genes present in the 
isolates. With the MinION data, only the plasmid which was able to be conjugated or 
transformed in vitro was sequenced. Not all β-lactamases from the original isolates were 
present on the isolated plasmids. These other β-lactamases which were not transferred 
are also shown in Table 6. A CTX-M ESBL gene plasmid was transferred from 15 of the 
16 (93.75%) isolates wherein CTX-M types and TEM/SHV/OXA type co-occurred. In the 
one exception a TEM-1B gene was isolated rather than CTX-M-14. There was also a 
plasmid isolated which carried both CTX-M-15 and TEM-1B, though it should be noted 
the ESBL determinant was CTX-M-15. In the two isolates where CTX-M-14 and CTX-M-
55 co-occurred, a plasmid encoding only CTX-M-14 was isolated. 
 
 
There were two cases of incongruence. One plasmid isolated was found to carry a SHV-
183 ESBL gene, despite this gene not being identified in the Illumina WGS results (which 
identified CTX-M-14 and TEM-1B). In another instance, a plasmid which carried CTX-M-
15 and TEM-127 was identified from an isolate which only carried OXA9/SHV-12/TEM-
1A β-lactamase genes according to the Illumina WGS results. In both cases the 
anomalous gene (SHV-183 and CTX-M-15 respectively) was found in the raw MinION 
reads using the EPI2me resistance workflow. The WGS unfiltered Illumina reads were 
also assessed using CARD and the CGE ResFinder to ensure these anomalous genes were 
not missed due to differences in resistance gene databases; the genes were absent. The 




genes were also absent in the bowtie2 filtered Illumina reads. Furthermore, no β-
lactamase gene was present in both sets of bowtie2 filtered Illumina reads at all 
according to the CGE ResFinder. Thus, it appears these anomalies were caused by an 
error in the MinION analysis, probably due to contamination. For this reason, these two 
plasmids were excluded from later analyses. 
 
Table 6: Beta-lactamase genes encoded by isolated plasmids 
Beta-lactamase gene 
encoded by isolated 
plasmids (MinION) 
Beta lactamase genes 
present in original isolate 
(Illumina WGS) 
Number 
CTX-M-14ᵞ CTX-M-14 3 
CTX-M-14/CTX-M-55 2 
CTX-M-14/TEM1B 3 
CTX-M-15 ᵞ CTX-M-15 4 
CTX-M-15/OXA-1 3 
CTX-M-15/OXA-1/TEM1B 1 
CTX-M-15 ᵞ/TEM-1B* CTX-M-15/CMY/TEM1B 1 
CTX-M-15 ᵞ/TEM-127* κ OXA9/SHV-12/TEM1A 1 
CTX-M-27 ᵞ CTX-M-27 12 
CTX-M-27/OXA-1 2 
CTX-M-27/TEM-1B 2 
CTX-M-55 ᵞ CTX-M-55 1 
CTX-M-55/TEM1B 3 
SHV-12ᵞ SHV-12 1 
 SHV-12/TEM1B 3 
SHV-183x κ CTX-M-14/TEM1B 1 
TEM-81+ SHV-12/TEM1B 1 
TEM-1B* CTX-M-14/TEM1B 1 
*=broad-spectrum beta-lactamase phenotype 
+=inhibitor resistant beta-lactamase phenotype 
x=phenotype undefined 
ᵞ =ESBL phenotype 




The proportions of different sequence types from which a plasmid was able to be 
isolated was largely consistent with the proportions observed in the full set of isolates. 
ST131 made up the largest portion (17/43, 39.5%), followed by ST38 (4/43, 9.3%), 
ST405 (4/43, 9.3%) and ST636 (4/43, 9.3%). With the exception of ST14 and ST95, at 




least one isolate of all sequence types present in the full set of isolates was able to be 
isolated by transformation or conjugation. Therefore, MLST type did not affect the 
ability to isolate an ESBL-encoding plasmid.  
 
 
When considering the combination of MLST and ESBL gene type there were some 
differences. In the group of isolates from which CTX-M-14-encoding plasmids were 
isolated, only one (1/8, 12.5%) was from a ST131 isolate, despite 31.6% (6/19) of all 
CTX-M-14 encoding isolates being ST131. In contrast, a CTX-M-14-econding plasmid was 
isolated from all 3 of the CTX-M-14 positive ST405 isolates. A CTX-M-14 encoding 
plasmid was also isolated from 1 each of the other MLST types, except for the ST10 and 
ST38. In contrast, the proportions of different MLST from which a CTX-M-27 encoding 
plasmid could be isolated (11/16, 68.75%) was consistent with the distribution of MLST 
in all 66 isolates (the full set), with ST131 making up the majority (13/18, 72.2%). While 
ST131 was the most common MLST from which a CTX-M-15 encoding plasmid was 
isolated (3/9, 33.7%), it represented a smaller proportion than in the full set (7/15 
46.7%). The three CTX-M-15-positives isolates from which a plasmid could not be 
isolated were ST648, ST405, and ST131. A plasmid could be isolated from all but two of 
the CTX-M-27 encoding ST131 isolates (11/13, 84.6%). Of the CTX-M-55 (excluding the 
co-occurring CTX-M-14 isolates), only the ST95 was not transformed. Figure 18 
illustrates the diversity of MLST types from which an ESBL-encoding plasmid was 
isolated, with variation in the ESBL gene indicated. The two excluded isolates encoding 
SHV-183 and CTX-M-15/TEM-127 were from ST10 and ST127 MLST isolates 
respectively (not shown in figure). 
 
 





Figure 18: Plasmid encoded beta-lactamase genes and MLST of host E. coli. ESBL 
genes encoded on plasmids were determined by hybrid assembly of MinION and 
Illumina plasmid reads. MLST of host E. coli were determined from Illumina WGS data. 
 
 
 Plasmid Incompatibility Types 
Next, the plasmid incompatibility types of the isolated β-lactamase encoding plasmids 
were determined. Ten different incompatibility types were identified (Figure 19). Multi-
*=broad-spectrum beta-lactamase phenotype 
ᶧ=inhibitor resistant beta-lactamase phenotype 
ᵞ =ESBL phenotype 




replicon plasmids were common in this set of isolates, with three different types of 
multireplicons identified: IncFIA/IncFII, IncN/IncX4, and IncFIB/IncFII. Multireplicon 
IncFIA/IncFII was one of the two most common incompatibility types in this set of 
plasmids, alongside IncFII (both n=10, 22%). IncI1 also made up a significant portion of 
the plasmid population (n=8, 18%). The plasmid incompatibility type of 4 of the isolates 




Figure 19: Plasmid Incompatibility Types.  
 
 
Next, the plasmid incompatibility types were considered in context of the β-lactamase 
gene they carried and the MLST of the isolate from which they were isolated (Figure 20). 
There was a significant association between CTX-M-27 and IncF plasmids (p <0.05). 
The CTX-M-14/ST405 cluster of 3 isolates was revealed to be carried on three different 
plasmid incompatibility types (IncFII, IncFIA, and IncB/O/K/Z). In addition, the large 
cluster of CTX-M-27/ST131 was revealed to be carried on multiple different plasmid 
types (IncFIA/IncFII, IncFII and IncB/O/K/Z), though 7 ST131 isolates with a CTX-M-27-
encoding IncFIA/IncFII multireplicon plasmid were found. Only one other ST, ST405, 
carried an IncFIA/IncFII multireplicon plasmid, but that plasmid encoded CTX-M-15. In 
contrast, the SHV/ST636 isolates (n=3) all carried an IncX3 plasmid, and the CTX-M-
27/ST38 isolates (n=3) all carried an IncFII plasmid. The plasmid incompatibility types 


























commonalities of carriage, all four IncX3 plasmids encoded SHV. The majority of both 
IncFII and IncFIA/IncFII plasmids encoded CTX-M-27 (both 7 of 10, 70%). IncI1 
plasmids on the other hand carried mostly CTX-M-15 (50%, 4/8, 50%). The two 
excluded isolates encoding SHV-183/ST10 and CTX-M-15/TEM-127/ST127 were 




Figure 20: Beta lactamase genes, MLST and plasmid incompatibility types of 
plasmid hybrid assemblies.  
 
 
*=broad-spectrum beta-lactamase phenotype 
ᶧ=inhibitor resistant beta-lactamase phenotype 
ᵞ =ESBL phenotype 




 Insertion Sequences 
Insertion sequences surrounding ESBL genes on isolated plasmids were also able to be 
described. Insertion sequences found upstream of the ESBL genes in this study were 
ISEcp1, IS26, IS3000, ISEhe3, IS1b, and IS1X2, as well as transposases Tn2 and TnA. 
Downstream of the ESBL genes, orf477, IS903D, IS26, iroN, and IS15DI were found, as 
well as transposases Tn2, Tn3, TnA, tnpR, and deoR_TR.  
 
There were unambiguous differences in the insertion sequences around CTX-M genes 
and TEM/SHV genes. Insertions sequences such as ISEcp1, IS1X2, orf477, IS903D and 
iroN appeared around CTX-M ESBL genes only, while IS1b, IS3000, ISEhe3, tnpR and 
deoR_TR only appeared around TEM/SHV genes. The only commonalities were IS26 and 
TnA. There were also group specific differences. While ISEcp1 and IS26 appeared 
upstream of the ESBL gene regardless of CTX-M group, Tn3-like ISEcp1 only appeared 
upstream of CTX-M-15. In contrast the downstream insertion sequences showed stark 
differences between CTX-M groups, with IS903D variants appearing only in group 9 CTX-
M isolates, and orf477 variants appearing only in group 1 CTX-M isolates.  
 
 
The assemblage of these insertion sequences around ESBL genes is important, with 
more than one often appearing adjacent to the ESBL gene. As there are many insertion 
sequences (and combinations thereof) to consider, classification systems can ease the 
depiction of the diversity of the genetic context of the ESBL genes.  
 
 
 Letter Allocation Classification System 
In order to easily compare and assess insertion sequence associations a classification 
system was developed that ascribes a character for each insertion sequence and 
transposon (Figure 21). Based on this classification system, Figure 21 shows the 
proportions of each insertion sequence found around each ESBL gene type in this study. 
Each CTX-M had a major (most frequently found) insertion sequences type, as well as 
some minor populations. The CTX-M-15 and TEM1B genes that were found next to each 








We can observe that the insertion sequence combinations A-W (5’and 3’ of ESBL gene) 
and E-V were found surrounding both CTX-M-14 and CTX-M-27 (both group 9 ESBLs, 
differing by one substitution- D240G), and that these were the only insertion sequence 
combinations to occur with more than 1 ESBL gene type. However, E-V occurred mostly 
in CTX-M-27, forming a large group of isolates (7/16, 43.75%), with only one instance in 
CTX-M-14 isolates; while A-W occurred mostly in CTX-M-14 (4/8, 50%), with only one 
instance in CTX-M-27 isolates. Excluding A-W, all four other CTX-M-14 isolates had 
different surrounding insertion sequences. In CTX-M-27 there was a second smaller 
group with the same surrounding insertion sequence E-S (4/16, 25%).  
 
 
All the CTX-M-55 were different from each other in terms of insertion sequences. CTX-
M-15 isolates had high diversity with only B-Y (3/8,37.5%) and A-Y (2/8, 25%) 
occurring in more than one isolate; these differed only in the presence of Tn2 upstream 
of ISEcp1.  
 
 
All SHV-12 isolates had different surrounding insertion sequences (H-, L-P, I-P, L-O). In 
one of these (H-), the only insertion sequence identified occurred upstream of the SHV-
12 gene. The TEM genes (TEM-1B, TEM-81) also had differing surrounding insertion 











Figure 21: Surrounding insertion sequences by letter allocation system 
 
 
 OVERALL GENETIC DIVERSITY 
The overall genetic diversity can be considered by taking into account the ESBL gene, 
MLST, plasmid replicon type, and the insertion sequences surrounding the ESBL gene 
(Figure 22). This revealed that the three SHV/ST636/IncX3 isolates had different 
insertion sequences around the ESBL genes (L-O, L-P, and H-). Similarly, the three CTX-
M-15/ST131 isolates had three different surrounding insertion sequences (B-X, A-Y, and 
B-Y). The CTX-M-27/ST131/IncFII isolates had one of two different surrounding 
insertion sequences (E-T and D-V). In contrast, the CTX-M-27/ST131/IncFIA+IncFII 
isolates were all EV class insertion sequences, though one of the isolates was also 

























































It is also apparent that there were some commonly occurring insertion sequences 
surround certain CTX-M-genes, that were in fact on plasmids of different incompatibility 
types and in isolates with different MLST profiles. For example: CTX-M-14 with A-W was 
on 4 different plasmids, carried by isolates with 4 different sequence types. CTX-M-15 
with B-Y were all on plasmids of the same incompatibility type (IncI1), but were carried 
by isolates of different sequence types. The incompatibility type of the plasmids 
encoding CTX-M-15 with A-Y surrounding insertion sequences was unable to be 
identified in two cases and IncI1 in the other, but they were all from isolates of different 
sequence types.    





Figure 22: Full Genetic Diversity of ESBL E. coli  
Finally, the core genome (Figure 23) and pan genome phylogenetic trees (Figure 24), 
obtained from WGS analysis, were annotated with all available information on ESBL 
gene, sequence type, plasmid incompatibility type, and surrounding insertion sequences 
(149). The isolates which were identical across all four assessed criteria are highlighted. 
While there is a cluster of six (6/66, 9.1%) identical isolates (ST131 isolates with 
plasmid CTX-M-27/E-V/IncFIA/IncFII), and two smaller clusters (two [2/66, 3.0%] 
ST131 isolates with plasmid CTX-M-27/E-T/IncFII; three [3/66, 4.5%] ST38 isolates 
with plasmid CTX-M-27/ES/IncFII), the majority of isolates appear to be genetically 
diverse.  
*=broad-spectrum beta-lactamase phenotype 
ᶧ=inhibitor resistant beta-lactamase phenotype 
ᵞ =ESBL phenotype 




   
Figure 23: Core genome SNP phylogenetic tree labelled with ESBL genes and 
genetic context. Identical isolates in terms of gene, insertion sequences, plasmid 
incompatibility type and MLST are marked with the same colour. Graph generated and 
annotated using iTOL online (version 3.0) reference (149) 
 





Figure 24: Pan genome phylogenetic tree labelled with ESBL genes and genetic 
context. Identical isolates in terms of gene, insertion sequences, plasmid incompatibility 
type and MLST are marked with the same colour. Graph generated and annotated using 
iTOL online (version 3.0) reference (149) 





In this study, I characterized the genetic context of resistance and the phylogenetic 
relationship of ESBL E. coli isolated from urine from Otago between February 2015 and 
January 2016.  A diverse array of ESBL genes, sequence types, plasmid types, and 
insertion sequences were found; suggesting that the recent increase in incidence in 
uropathogenic ESBL Escherichia coli in Otago is due to multiple introductions.  
 
 CLINICAL ISOLATES 
All non-duplicate ESBL E. coli isolated by SCL from the Otago community and from 
Dunedin Hospital that were available were characterized in this study. That is, the whole 
population (n=82) of that year rather than a random selection.  However, some isolates 
(n=13) were missing from storage. This represented only 15.9% of isolates and no 
systematic bias was apparent. In a previous study, three cryopreserved isolates were 
found not to be ESBL producers as had been reported; two were presumptive AmpC β-
lactamase producers and one was susceptible to cefpodoxime (78). This may have been 
due to sampling error during storage in the presence of a double population of 
ESBL/non-ESBL bacteria. Therefore, the isolates in this study are an accurate 
representation of the diversity of ESBL E. coli causing urinary tract infections in the 
Otago community in 2015. 
 
 
 SPECIES IDENTIFICATION 
Whole genome sequencing confirmed that all isolates were E. coli. Kraken (0.10.5) was 
the bioinformatic tool used for species identification in the Nullarbor pipeline (131,152). 
Kraken queries a look up table in a constructed database for exact k-mer matches and 
stores the lowest-common ancestor (LCA) if a k-mer is found in two or more taxa 
(152,153).  The observed identity classification percentages (range 33.24%-82.23%, 




median 72.69%) for the first match are expected for Enterobacteriaceae using kraken 
(152,153). The genera in the family Enterobacteriaceae have a high sequence similarity, 
posing difficulties for any classifier (152,153). Though the identity classification 
percentage was low in many of the isolates, the second match had very low identity 
percentage (<2.28%) comparatively in all isolates, making the identification of E. coli 
acceptable. The isolates had also all been confirmed as E. coli in a previous study using 
MALDI-TOF MS (78).    
 
 
 MLST AND PHYLOGENETIC ANALYSIS OF ISOLATES 
The core genome is defined as the genes common to all strains of a species (39). The 
accessory genome represents the genes not common to all strains of a species (39). The 
pan genome refers to the entire set of genes - the combination of both the core genome 
and accessory genome (39). The Nullarbor bioinformatic pipeline uses Snippy and 
FastTree to construct a core genome phylogenetic tree. Snippy finds SNPs between the 
assigned reference (in our case an ST131 CTX-M-15 ESBL E. coli) and all the isolates, 
producing an alignment of the SNPs on genomic positions that are present in all samples 
(known as “core sites”) (134). FastTree is used to construct the phylogenetic tree 
(131,135). The Nullarbor bioinformatic pipeline uses Roary to construct a pan genome 
phylogenetic tree with the input being annotated contigs (136). Roary takes into account 
full sequences of coding regions, and clusters isolates based on gene presence in the 
accessory genome (includes putative coding genes absent from one or more isolates), 
weighted by cluster size. There were a few (6-7) clusters evident in the core genome 
phylogeny tree, while the pan genome phylogeny tree showed several (9-10) smaller 
clusters. The variety in the pan genome phylogeny suggests some variation in the 
accessory genome. There are subgroups evident in the pangenome tree of the closely 
clustered isolates seen in the core genome phylogeny, suggestive of a shared accessory 
genome, and thus in the encoded mobile genetic elements. In a previous study, 
subgroups in the accessory genome of isolates that are closely related in core genome 
(with the same MLST [ST131]) has been described, with certain IncF plasmid allele 




types associated with different ST131 sublineages, and further subgroups of IncF 
plasmid allele types (F29:B10 and B1) in the sublineage of H22 (154). 
 
 
Nullarbor uses mlst which scans contig files against traditional (autodetected) PubMLST 
typing schemes using the NCBI Basic Local Alignment Search Tool (BLAST+) blastn 
database to identify the MLST of each isolate (131). The advantages of using MLST are 
that it is well established and can therefore be used for standardised comparisons across 
studies, can be used in both WGS, older methods, and in future genome sequencing 
methods, and allows for direct interpretation (74). 
 
 
Worldwide, many E. coli sequence types have been identified to produce an ESBL (2,15). 
In this study the most common ST identified was ST131 (42.4%). Though it did not 
represent the majority of STs as seen in many countries internationally, the proportion 
found in this study is within reported ranges of 23-64% (3,4,15,16,25). This percentage 
was also lower than that seen nationwide in the 2013 ESR survey (54.5%, 122/224) and 
the 2016 ESR survey (60.1%, 176/293). The ESR surveys describe the nationwide 
hospital and community ESBL populations in New Zealand over a 1-month period. 
ST131 has been implicated in the rise in ESBL resistance worldwide, and is particularly 
important in ESBL resistant urinary tract infections due to their increased biofilm 
formation ability and common resistance to fluoroquinolones (3,4,14-17,19). 
 
 
The second most common ST in this study, ST38 (7/66= 10.6%), was found at a similar 
frequency in the 2016 ESR survey (6.8%, 20/293); only ST131 was tested for in the 
2013 ESR survey (13). ST38 has previously been identified as a MDR high risk clone, 
which is predominantly associated with urinary tract infections (14). This clone has 
been observed as one of the most common MLSTs in countries such as Saudi Arabia 
(Jeddah [2018] and Riyadh [2015]), Germany (2014), Korea (2012), Canada (2000-
2010), Denmark (2017) and to a lesser extent from 2000-2010 in Norway, Japan, Spain, 
Turkey, France, and North America (14,19,22,36,73,155-159). Asymptomatic human 
faecal carriage has been reported, and it has also been observed in environmental 
bacterial populations isolated from animals (including fish), vegetables, and water, in 




countries including Switzerland, Germany, the Netherlands, the United Kingdom, India, 
Thailand, and Vietnam (19,33,160-162). 
 
 
ST405 (7.6% and third most common in this study, 2.4% and the seventh most common 
in the 2016 ESR survey) and ST648 (4.5% in this study, 2% in the 2016 ESR survey) 
were the only other MLST types that appeared in more than two isolates in both studies. 
ST405 has been important in the spread of CTX-M worldwide in the past (19). ST405 has 
also been linked to fluoroquinolone resistance and has been isolated in Norway, Kuwait, 
Spain, Switzerland, Belgium, France, Japan, Korea, Thailand and Australia; it has often 
been identified as one of the more common MLST types in ESBL E. coli (19,163-165).  
 
 
Both my study and the 2016 ESR survey showed a high degree of diversity in STs. The ST 
of 12.2% of isolates (36/293, 25 different STs) in the ESR survey and 28.8% of isolates 
(19/66, 17 different STs) in this study were shared by less than or equal to 2 isolates. 
The higher rate in this study likely represents under-sampling due to the smaller sample 
size. There were 22 different non-ST131 STs in this study and 33 different non-ST131 
STs identified in the ESR 2016 study. Some STs,  which had low incidence in this study 
including ST69 (2/66, 3.0%), ST73 (not isolated), ST95 (1/66, 1.5%) and ST1193 (1/66, 
1.5%), have been reported with high incidence in international regions in Europe 
(United Kingdom, Germany, Netherlands) and USA (California) (2). ST1193 was the 
third most common MLST in the 2016 nationwide ESR study (6.8%, 20/293). In 
summary, the dominance of different clones varies between countries and different 
regions with countries, with the exception of ST131.   
 
 
 PLASMID ISOLATION 
Both conjugation and transformation were used for isolation of the ESBL-encoding 
plasmid. The conjugation method better demonstrates the transferability of these 
plasmids in the environment, as opposed to electroporation. The efficiency of the 




conjugation method should also be considered. Cefotaxime was chosen to select ESBL 
transconjugants as CTX-M type ESBLs (most common in this set of isolates) display a 
higher affinity for cefotaxime than ceftazidime, and in the previous study with these 
isolates, 15 isolates did not display synergy with the ceftazidime/ceftazidime + 
clavulanic acid double disc diffusion test (5,10,13,15,18,19,78). The filter mating method 
was chosen as studies have shown this method to have higher transfer rates than liquid 
conjugation and solid phase conjugation (118,166). In agreement with these studies, 
previous attempts with liquid conjugation with this set of isolates gave low transfer 
rates (17/66, 26%), while the filter mating conjugation method was nearly twice as 
successful (33/66, 50%) (78). A previous study by Sasaki et al. found a higher frequency 
of conjugal transfer with a 0.45 µm filter compared to a 0.22 µm filter (167). The use of a 
0.45 µm filter in my study allowed the transfer of 1 isolate (out of 5) that was not able to 
be transferred with a 0.22 µm filter. Using a larger sample size would have allowed a 
better comparison. A further five isolates run with the 0.45 µm filter were all 
successfully conjugated, so this filter was used for all isolate conjugation experiments. 
The study by Sasaki et al. also found that passing sterilized water or PBS through the 
filter under reduced pressure (about-50cmHg) before filter incubation increased the 
transfer rate (167). The use of this technique may have improved the transfer rate but 
was not attempted due to constraints of time, equipment, and cost. The large size of the 
plasmids (40-150 kb) may have affected transferability under laboratory conditions 
(127). A plasmid was able to be isolated from isolates of nearly all MLST types (except 
two). All MLST types carried transferable plasmids, and none in particular were 
associated with highly transmissible plasmids. 
 
 
Successful electroporation was achieved in 12/33 (36.6%) plasmid isolates where a 
plasmid could not be transferred by conjugation. Electroporation was chosen over 
chemical treatment due to its higher efficiency (127). Methodology was refined during 
the project. DH10B was chosen as the it showed higher efficiency for large plasmids 
compared to other strains (H5a, XL-1 BlueMR, JS4 and HB101) in a previous study (127). 
The optimal electrocompetent cell volume was determined to be 40 µL (8x109 cells) in 
this study compared to 20 µL (4x109 cells), though only a small subset (6 plasmids) was 
used to test this. This was done as a previous study has shown cell concentration has an 
effect on transformation, with the peak being 5-6x109 cells (168). Similarly, the optimal 




plasmid DNA concentration has previously been determined to be 10 to 40 pg (168). In 
my study 40-80 ng/µL was determined to be the optimal concentration, but again this 
was with a limited number of dilutions and test plasmids. The default settings of 1.8 kV 
(18 kV/cm), 200 ohm, 25 µF in a 0.1 cm cuvette were used for electroporation. I did not 
attempt to determine the optimum electroporation conditions due to time constraints. 
In pervious studies, the optimum conditions for plasmids >80 kb was determined to be 
13 kV/cm (field strength), 100 ohm (resistor), 25 µF (capacitor) in a 0.2 cm cuvette 




The modified alkaline lysis method was used to isolate plasmids from clinical isolates for 
electroporation, and from transformants and transconjugants for sequencing on the 
MinION. Nanodrop spectrophotometer was used to assess the purity of the extracted 
plasmids. The A260/280 values for both experiments were higher (1.92- 2.18) than the 
benchmark for purity (1.8) even after cleaning with Agencourt AMPure XP beads 
(Beckman Coulter, High Wycombe, UK). The A260/230 values of plasmids extracted for 
electroporation were lower (1.23-2.15) than the purity benchmark (2.0-2.2). The 
A260/230 values of plasmids extracted from the transformants and conjugants were 
higher (2.48-2.52) than the purity benchmark. Contamination with an extraction reagent 
such as phenol or an acidic pH normally lowers the A260/280 ratio (124,125). Higher 
A260/280 ratios are seen in basic solutions (124,125). The ratio is also dependent on 
the composition of the nucleic acid, as the different nucleotides display varying 
A260/280 results (124,125). A260/230 values were higher than the respective 
A260/280 values, which is expected in “pure” nucleic acid. The A260/230 ratios lower 
than 2.0 that were observed in the electroporation plasmids may be due to the presence 
of co-purified contaminants (124,125). 
 
 




 MINION AND BIOINFORMATICS 
MinION based sequencing is a new technology, with improved techniques and 
bioinformatic software being developed rapidly (94). This has presented a challenge for 
ideal experimental design and resulted in each batch being processed differently. For 
example, the MinKNOW software was updated from version 2.0 to 2.1 during the study.  
MinKNOW 2.0 included a new graphical user interface as well as improvements such as a 
progressive unblock mechanism that improves removal of problematic strands by using 
progressive flicks instead of only a single flick, a dynamic voltage control that tracks 
current to adjust voltage as needed rather than in fixed steps at set time intervals to 
better stabilize run conditions throughout the experiment (170).  MinKNOW 2.1 changed 
the mux scan (ranking of pores by quality) from a latching mechanism to a time based 
assessment, increased ‘chunk’ size (sectioning of raw signal data for base calling), and an 
improvement to the unblock mechanism to prevent incorrect ejections (171). These 




There were also differences in pre-analytical steps that may have resulted in inter-batch 
differences. From the variation in the four Minion runs that were performed, it appeared 
that the sequence quality decreased with storage of plasmids for longer periods of time, 
suggesting plasmid degradation. The run with plasmids that had been stored for the 
longest (run 3: stored 3 weeks at -20oC) had the lowest average yield, read length, and 
quality score, though not the lowest quality score mode. Yet it appeared that storage at -
20oC for 2 days (run 1 and run 4) did not affect sequence quality compared to plasmids 
that were never frozen and run on the day of isolation (run 2), with both run 1 and run 4 
having a higher quality score, and run 4 having a higher read length average than run 2.  
However, the age of the flow cell may have affected the results obtained with the fresh 
plasmids, with run 4 being run on a new flow cell, and run 1 being run on a flow cell 
used only once before. 
 
 
In addition, only one batch was run with each condition, so more replicates would be 




required to confirm these observations. Even so, rerunning on fresh flow cells or with 
plasmids with shorter storage time may have improved yield and quality. 
Inconsistencies between runs have been described in previous studies, with one study 
reporting differences between runs in the same laboratory as well as between two 
different laboratories, though the rapid kits were better than others in terms of yield 
consistency, especially with simpler library preparation, though it was difficult to 
predict yield (94). 
 
 
Different run times were also used between batches. Two batches (run 1 and 4) were 
sequenced for 5-6 hours, while the other two batches were sequenced for 12 hours (run 
2 and 3). The 12 hour runs were necessary as DNA library preparation was carried out 
during the day and sequencing performed overnight. Batches 2, 3 and 4 were not 
basecalled live to prevent data loss from lost connections; instead raw reads (.fast5) 
were later basecalled with Albacore to produce .fastq files. The first batch was base 
called live with MinKNOW which outputs only fastq files, so fast5 files for were not 
available to later analyse with the albacore pipeline used for the other isolates.  
 
 
Yield (in Mbp) was more dependent on read quality (measured by quality score) than 
run duration. The first run with an average quality score of 11.53 had a yield of 20Mbp 
in 5 hours (4 Mbp/h), the second run with an average quality score of 9.705 had a yield 
of 50.94 Mbp in 12 hours (4.25 Mbp/h), the third run with an average quality score of 
9.535 had a yield of  6.86 Mbp in 12 hours (0.57 Mbp/h), and the fourth run with an 
average quality score of 10.4775 had a yield of  37.11 Mbp  in 6 hours (6.19 Mbp/h). Run 
3 had a lower yield than run 1 and 4 despite being run for longer, and run 4 had a higher 
yield per hour than run 2. The fact that most pass reads are generated early in the run 
has been previously established (99). The maximum run time of 48 hours was not 
utilized. A previous study reported that only 31 pass reads were generated in the final 
12 hours of a 48 hour run, with 50% of pass reads generated in the first 6 hours, and 
90% of pass reads generated at 12 hours, suggesting that running for longer than 12 
hours is unnecessary (99). However, in the same study, using only pass reads from the 
first 6 hours was less accurate than using 6 hour pass reads in addition to selections of 
pass reads from 6-12 hours. Therefore, it is possible that extending run 1 and 4 beyond 




5-6 hours may have improved plasmid assembly. In contrast, the lower quality of reads 
beyond 6 hours may have affected the quality score average of run 3 and 2, both 
sequenced for 12 hours. 
 
 
Despite differences in yield and quality score between runs, most plasmids were able to 
be completed using bowtie2 and Unicycler, suggesting that the quality and yield of 
sequence data were sufficient for the scope of this project. All isolates where the plasmid 
type was not found were from runs 1 and 2, which had a quality average of 11.53 and 
9.71 respectively. These quality scores were higher than the quality score of run 3 
(9.5375) There were incomplete plasmids from each of the 4 runs. Therefore, variation 
in individual plasmid and library preparation quality may have been more important 
than variations between runs (keeping in mind there were only 4 runs) for insufficient 
sequencing data. In addition, large repeat structures may still cause problems when long 
reads are used if these repeats are longer than the MinION reads (83,100,102,109). 
Underrepresentation of homopolymers (stretches of identical bases) still pose a 
problem; though in one study Miniasm performed better than Canu in this regard, only 
the use of a polishing software such as Nanopolish sufficiently improved homopolymer 
detection (83,100,102,109).  
 
 Basecalling 
The base caller used in this study, Albacore, has been shown to have greater speed and 
read accuracy than other base callers such as Guppy and Chiron in a comparison by Wick 
et al (172,173). Other advantages of Albacore include multi-threading support, the 
ability to base call fastq files, and a command line interface (109,174). However, 
Scrappie has similar speed and is more accurate in resolving homopolymers (174).  
 
 
The version of Albacore used in this study includes demultiplexing. Porechop was also 
used to remove adaptors. Porechop also includes demultiplexing, and when Porechop 
disagrees with Albacore the read is discarded. This provides a two-step confirmation 




which can decrease the likelihood for misfiled barcodes but can also result in barcodes 
being erroneously discarded. As Porechop was not trained on the rapid barcoding kit 
used in this study, its accuracy in demultiplexing may be lower than applications like 
Deepbinner which was trained and designed for this kit (174). However, Deepbinner 
requires raw reads (.fast5 files) which were not available for the first run.   
 
 Miniasm/SPAdes 
I first used Miniasm to construct long read assemblies due its faster turnaround time 
compared to other long read assemblers such as Canu. Miniasm can take as little as 2 
minutes, whereas Canu takes approximately 2 hours to complete 1 assembly (99,109). 
However, without a polishing step, with nanopolish for example, Miniasm is less accurate 
than Canu. An error correction step would have increased the accuracy of the Miniasm 
long read assembly, but this would also have significantly increased the turnaround 
time. For example, using nanopolish could increase the turnaround for one assembly to 
over 24 hours, even though nanopolish can improve consensus accuracy to 99.9% 
(98,99,139,172). I hypothesised that a polishing step or the use of the more accurate 
Canu was not required as Illumina reads would essentially be used for error correction 
in hybrid assembly with SPAdes. In a previous study, the use of nanopolish or Racon to 
polish prior to hybrid assembly with SPAdes resulted in accuracy exceeding 99.99% 
(98). Hybrid assembly with SPAdes has similar accuracy to Canu long read assemblies 
(98,99,100). In another study hybrid SPAdes was able to produce single circular 
plasmids, however in our study none of the isolates run with hybrid SPAdes resulted in 
complete plasmids carrying the ESBL gene (175). Instead a fragmentated assembly was 
obtained with the CTX-M gene located on one of the many divergent nodes of the 
chromosome where short read sequences failed to fully resolve the genome. Incorrect 
integration of plasmids into the bacterial chromosome has previously been reported 
with SPAdes (99). 
 
 
The use of plasmidSPAdes was also attempted on a subset of samples because this was 
designed for plasmid assembly. However, this did not greatly improve plasmid 
completion, and resulted in fragmented assembly or incorporation into chromosomal 




reads. This is in agreement with previous studies where plasmidSPAdes actually had less 




Unicycler first uses SPAdes to assemble Illumina reads followed by Racon in conjunction 
with Miniasm for hybrid assembly. Racon has been shown to improve median accuracy 
of reads from 89.8% to 99.25% (109). Racon/Miniasm (97.7%-99.32%) has similar 
accuracy to Canu (96.87%-98.61%), while also being an order of magnitude faster (109). 
Unicycler also uses Pilon for polishing, which has been shown to improve plasmid 
resolution in previous studies (100,101,139). The original paper describing Unicycler 
compared its performance to other hybrid assemblers. Unicycler assembled larger 
contigs with fewer misassemblies, even when long-read depth and accuracy were low 
(139). This is consistent with my study where Unicycler also performed better than 
Miniasm/hybridSPAdes and Miniasm/plasmidSPAdes. 
 
 
 Bowtie2 Filtration 
Bowtie2 filtering was used to remove non-plasmid sequences prior to assembly in all 
cases where a complete plasmid was unable to be obtained with Unicycler alone. If a 
complete plasmid was obtained without bowtie2 filtering, these samples were not rerun 
with bowtie2 filtering; that is the best result was used for plasmid completion. Only a 
small subset of 5 (5/25, 20%) were rerun with the bowtie2 prefilters for comparison 
and validation of the use of bowtie2. Most of these (4/5) gave similarly completed 
plasmids, with only one of these isolates resulting in a linear plasmid with the bowtie2 
prefilter. In addition, in a previous study, aggregation of the results of different methods 
(in that case Canu, hybridSPAdes and plasmidSPAdes) allowed the completion of more 
plasmids (29/37 vs 26/37) (100). A similar approach was taken in this study in either 
using bowtie2 filtering or using Unicycler alone in order to maximise number of 
completely resolved plasmids as efficiently as possible. Since the same assembler is used 




downstream of filtering, the only difference is in the short-read inputs to the assembler 
when filtration is applied. Removal of non-plasmid sequences may make the assembler 
less prone to error than when MinION plasmid reads are matched to Illumina whole 
genome sequences reads during local match assembly. In only 1 case (1/5, 20%) did 
bowtie filtering perform worse than without bowtie filtering. This may have been due to 
bowtie2 removing reads in a non-uniform manner, especially in hard to assemble 
regions. In a previous study the use of filtlong to filter reads by quality and Canu for 
correction lead to inferior assemblies (177).    
 
 
 Errors in Minion Results  
In the two cases of incongruence a plasmid was identified which carried a gene that was 
not identified in the Nullarbor report of the Illumina reads. One of the plasmids isolated 
was identified as a carrying a SHV-183 gene despite only CTX-M-14 and TEM-1B being 
identified by the Illumina sequence analysis using Nullarbor. In the other instance, a 
plasmid which carried CTX-M-15 and TEM-127 was identified from an isolate which 
only carried OXA9/SHV-12/TEM-1A β-lactamase genes according to the Illumina results. 
According to AGICard and the EPI2me resistance profile these incongruous genes were 
present in the raw MinION reads. This excludes the possibility of errors with bowtie or 
Unicycler further down the bioinformatic analysis pipeline. According to CARD and the 
CGE ResFinder the gene was absent in both the bowtie2 filtered and unfiltered Illumina 
reads. Thus the anomalous genes were not missed by Nullarbor due to reference library 
differences. Furthermore, no β-lactamase gene was present in both sets of bowtie2 




While, the MinION is known to have a high error rate, it is unlikely to explain the 
detection of a gene not present in the Illumina data (83,109). While isolates were 
subcultured and stored on several occasions since 2015, acquisition of a new gene is not 
plausible. Errors in Illumina sequencing are unlikely, as it is known to be more accurate 
than the MinION (177). 




The most likely explanation is carryover contamination in the MinION reads. As this 
library preparation kit used contained 12 barcodes and these were reused between 
batches, it is possible that this may be due to contamination from previous runs despite 
flushing of the flow cell post use, as recommended. Though these barcodes were not 
used for isolates containing the respective incongruent gene in my experiments, the 
same flow cell had been used for other experiments with E. coli genes. Carryover 
contamination of barcodes from previous libraries run on the same flow cell despite an 
intervening wash step has been observed in other studies (94,178). These contaminant 
barcodes may also be of high quality, and therefore not excluded by quality cut-offs (94).  
 
 
The use of a quality assessment tool such as QUAST, Plantagora, and GAGE to assess the 
quality of assemblies may have been useful. However, these tools have limitations: 
QUAST requires a known reference genome. We saw a wide variation in this set of 
isolates and natural variations may be mistaken for misassemblies in this case (179). In 
addition, the quality of the reads themselves have already been assessed.  
 
 
 IDENTIFICATION OF THE ESBL GENES 
 Dominance of CTX-M Genes 
As expected given the rise to dominance of CTX-M genes worldwide, the proportion of 
CTX-M gene carrying E. coli (86.4%) far exceeded the proportion of isolates which only 
carried a TEM, SHV, or OXA gene (13.6%) according to Illumina WGS (5,9,15,18,19). 
Interestingly, this ratio is lower than in the 2016 ESR study, which describes the 
nationwide hospital and community ESBL populations in New Zealand over a 1 month 
period (August), where 99% of isolates carried CTX-M type and 1%  carried a TEM, SHV, 
or OXA gene only (13). This difference may reflect Otago being a low prevalence area 
(17,21). Unfortunately, there was no ESR survey conducted in 2015, which is the year 
the samples in this study were collected; as of 2014, national surveys will be conducted 
every other year (13).  




 Co-occurrence of CTX-M and TEM/OXA Genes 
The commonality of TEM and OXA genes co-occurring with CTX-M genes (27/66, 40.9%) 
is consistent with previous studies (180,181,182). These genes may be either located on 
the same plasmid, different plasmids, or on the chromosome. Of the isolates encoding 
both a CTX-M and a TEM or an OXA gene, the 14 of 16 (93.75%) plasmids isolated 
encoded only a CTX-M ESBL gene. There was only one plasmid isolated that encoded 
both CTX-M-15 and TEM-1B genes. There were also two plasmids isolated which 
encoded only a TEM gene- TEM-81 from a SHV-12/TEM-1B isolate and TEM-1B gene 
from an CTX-M-14/TEM-1B isolate. This suggests that the TEM or an OXA genes were 
likely encoded on different plasmids or on the chromosome. The TEM and OXA genes 
identified are known to have a broad spectrum  -lactam resistance phenotype and have 




Similarly, the CTX-M-14 gene of the isolate from which the TEM-1B carrying plasmid 
was isolated may have been encoded on different plasmids or the chromosome. 
Chromosomal integration of CTX-M type ESBL genes has been reported in bacterial 
isolates from both animal and human populations of Europe, Asia and less commonly in 
the Americas. CTX-M-14 integration in particular was found commonly in one study in 
Japan (9,185-190). Previous studies have also found TEM1B in conjunction with CTX-M 
type ESBL genes (CTX-M-1) on the same plasmid (42). 
 
 
 TEM Genes on Plasmids 
Two plasmids isolated carried only a TEM β-lactamase gene.  Plasmids encoding a TEM-
1B (broad spectrum β-lactamase) gene and a TEM-81 (inhibitor resistant β-lactamase) 
gene were isolated from E. coli ST131 and ST636 isolates respectively. The plasmid with 
the broad-spectrum β-lactamase TEM-1B gene may also have encoded another 




resistance mechanism (e.g. an efflux pump) which increased resistance to CTX during 
growth of the transformed isolates on CTX containing agar.  
 
 
 SHV ESBL Genes 
No SHV genes were found in conjunction with CTX-M genes, though this co-occurrence 
has been described in the past (144-146,180-182). All SHV genes in this study were 
SHV-12, which is known to have an ESBL phenotype (144-146). SHV-12 encoding 
plasmids in Enterobacteriaceae have been found in aquatic environments in Switzerland, 
Portugal, Croatia, Canada, and China (59). They have also been found in food producing 
animals, companion animals, and wildlife in Spain, Portugal, Japan, Netherlands, Poland, 
the Czech Republic, China, Italy, USA, Mexico, and Germany. They have also been 
identified in vegetables in Switzerland, South Korea, Netherlands, and Spain (59).  They 
have also been identified in human clinical specimens in Tunisia, France, Korea, Italy, 
France, the United Kingdom, Netherlands, Portugal, Spain, Taiwan, and Bulgaria (59).  
 
 
 CTX-M ESBL Genes  
In the nationwide 2016 ESR survey, the proportions of CTX-M group 1 (CTX-M-15 and 
CTX-M-55) and group 9 (CTX-M-14 and CTX-M-27) genes in ESBL E. coli were 
approximately equal (50% and 49% respectively), though the proportion of group 1 
genes was slightly higher than group 9 (55.8%/43.3%) in 2013 (13,29). In my study 
group 9 ESBL genes (53.1%) had a higher incidence than group 1 ESBL genes (30.3%). 
This is also in contrast to most regions worldwide where group 1 has been dominant, 
but is in line with China, South-East Asia, South Korea, Japan, Spain, and South America 
where group 9 CTX-M genes are the most common (15,19,22,23,25-27).   
 
 




This difference is also reflected in the CTX-M types. In many countries, CTX-M-15 
increased from the early 2000s (pre-2005) to the late 2000s (2005-2008); this has been 
reported in Spain, Portugal, Italy, Canada (which went from CTX-M-27 dominance to 
CTX-M-15 dominance), USA, Mexico, Bolivia, Israel,  Egypt, China and Korea (though 
CTX-M-27 remained dominant in both), India, and South East Asia. While this increase 
continued in the 2009-2016 period in most countries, in other countries (Israel, Spain, 
North America (especially Canada), United Kingdom, Egypt, China, Vietnam, Turkey, 
France, Germany, Korea, and Japan) the proportion of CTX-M-15 dropped in favour of 
CTX-M-27, although not necessarily overtaking CTX-M-15 (22,34). There has also been a 
rise in CTX-M-1 and CTX-M-2 in some countries; not a single isolate of either was 
identified in my study (22). 
 
 
Prior to the 2016 ESR survey, data of CTX-M types in New Zealand was not available; in 
previous surveys, genes were only typed to the group. Therefore, it is not possible to 
assess any trends in CTX-M proportions in New Zealand, though the proportion of group 
9 ESBL E. coli has increased, suggesting the global trend may also apply to New Zealand. 
In Otago the incidence of CTX-M-27, CTX-M-14, and CTX-M-15 were not significantly 
different, though they represented the dominant genes over other CTX-M types, and the 
CTX-M-27 and CTX-M-14 proportions were higher than CTX-M-15, similar to the 
proportions reported from other countries, outlined above, where CTX-M-27 increased 
following 2009 (22). The 2016 ESR study only provided CTX-M gene proportions for all 
Enterobacteriaceae (including Klebsiella sp.) which were as follows: CTX-M-15, 54.5%; 
CTX-M-27, 22.7%; CTX-M-14, 14.2%; and CTX-M-55, 2.8%. Thus, the relative proportion 
of CTX-M-15 was lower in Otago in E. coli isolates. 
 
 
Theories that have been put forward for the growing success of CTX-M-27, including 
their higher minimum inhibitory concentration (MIC) to ceftazidime compared to CTX-
M-14 encoding isolates, a higher transmissibility in nosocomial settings, and 
transmission from animal sources where CTX-M-27 has been found commonly (22,31). 
The majority of the Otago isolates were from community setting (47/66, 71.2%) and the 
comparative MIC to ceftazidime was not assessed. There is no data available for whether 
the CTX-M-27 population has been increasing in Otago compared to the CTX-M-14 




population, or the presence of CTX-M genes in animal populations in Otago or other 
parts of New Zealand.  
 
 
Only four CTX-M- types were identified in this study. CTX-M types such as CTX-M-3 and 
CTX-M-1, CTX-M-24, CTX-M-9 and CTX-M-65 which were identified in the nationwide 
study were not identified in this study; this, along with the higher incidence of SHV 
ESBLs and OXA and TEM β-lactamases, may be attributed to the lower prevalence of 
ESBL E. coli in Otago (13,17,21). It may also represent under sampling due to the smaller 
number of isolates included in this study. 
 
 
Of interest are the two isolates in this study which carried two CTX-M types, namely 
CTX-M-14 and CTX-M-55. This phenomena of co-existing ESBL genes has previously 
been observed. In a study in China, 4.2% of isolates carried two or more CTX-M types, 
with most of these (6/10, 60%) being CTX-M-14 and CTX-M-55, as found in the current 
study (27). The nationwide study in 2016 also identified one isolate containing both a 
group 1 and a group 9 CTX-M (information on CTX-M type not available) as well as a 
further isolate with CTX-M-64 (first identified in 2010 Japan), which is thought to be a 
chimeric hybrid of CTX-M-14 and CTX-M-15 or CTX-M-55 (13,32). The exact origin of 
CTX-M-64 is unclear due to disagreements between studies with small sample sizes, 
which presents a significant problem given the variety in genetic context observed 
around ESBL genes. In any case, homologous recombination to create these chimeric 
CTX-M genes would require the simultaneous presence of both CTX-M types in the same 
cell, a condition that is observed in the two CTX-M14 and CTX-M-55-encoding isolates 
from this study. We did not observe a plasmid carrying both CTX-M-14 and CTX-M-55 or 
a hybrid gene; we isolated plasmids that carried only CTX-M-14 from these two isolates. 
 
 




 PHYLOGENETIC ASSOCIATION WITH CTX-M GENES 
MLST defines phylogenetic lineages in E. coli (39). Certain ESBL genes have been 
associated with certain sequence types, as defined by MLST, which accommodate 
transmission as they are highly virulent, multidrug resistant and highly transmissible 
(3,4,14-17,19). In contrast, a lot of diversity was observed in the CTX-M genes carried by 
isolates of many different MLST types in this set of isolates, with CTX-M-14, CTX-M-15 
and CTX-M-55 carried on many different MLSTs, and no strong associations with any 
particular MLST. Only a limited number of significant associations between CTX-M genes 
and MLST types were observed. 
 
 ST131 
An association between ST131 and CTX-M-15 has been described worldwide since the 
2000s and has been proposed to be the main reason for the pandemic of ESBL E. coli in 
most countries worldwide (14,22,30,31,191,192). This association has been reported in 
the United Kingdom, Canada, Italy, Turkey, Croatia, USA, South Africa, Brazil, Norway, 
Spain, France, Portugal, Switzerland, Lebanon, India, Kuwait, South Korea, Central 
African Republic , Indonesia , Tunisia,  Belgium, Denmark, Czech Republic, and Uruguay  
(14,22,30,31,191,192). Though the proportion of isolates with this association was more 
common in North America and Europe than in Asia (22). Additionally, in the 2016 ESR 
New Zealand study, an association between ST131 and CTX-M-15 was found (13). 
 
 
The results of this study were in contrast to these national and international reports. 
While ST131 was the most common MLST which carried CTX-M-15 (7/15, 46.7%), 
ST131 was only significantly associated with CTX-M-27 (13/18, 72.2%, p<0.01). An 
association between CTX-M-27 and ST131 has been reported in other countries where 
CTX-M-27 incidence is increasing or is greater than CTX-M-15, and where there is a 
dominance of ST131. These countries include Israel, the Czech Republic, China, 
Switzerland, Japan, France, Portugal, Germany, and Vietnam; the increase in incidence of 
ST131 associated with CTX-M-27 was mostly seen in these countries after 2010 (or the 




late 2000s) (22,30-37). Though in Japan CTX-M-27 was confined to ST131, this was not 
the case in Otago in this study, where more diversity was seen. Other countries where 
ST131 isolates carrying CTX-M-27 have been reported include Korea, Australia, Nepal, 
Cambodia, Spain, Netherlands, Canada, Denmark, and the USA (22,31,159,193). Overall, 
ST131 encoding CTX-M-27 may be considered an emerging issue. 
 
 
Of interest is the presence of CTX-M-27-encoding ST131 E. coli isolates in the 
environment, in contrast to CTX-M-15-encoding ST131 isolates and non-ESBL ST131 
isolates which are rarely found in the environment, including animals. CTX-M-27 
producing ST131 has been identified in asymptomatic human faecal specimens in 
France, China, Portugal, and the Netherlands; samples from sick dogs and cats in Japan; 
samples from water birds from central Europe and Swiss rivers and lakes; and samples 
of well water from China (22,31). This suggests the possibility of an environmental 




ST38 is not as ubiquitous as ST131, however it is one of the most common non-ST131 
MLST types associated with CTX-M ESBL production. In this study ST38 isolates carried 
CTX-M-14, CTX-M-55, and CTX-M-27 genes. On phylogenetic analysis there was a small 
cluster of three ST38/CTX-M-27 isolates, one of only two clusters identified in this study. 
ST38 has most commonly been found worldwide in association with CTX-M-14. E. coli 
ST38 encoding CTX-M-14 in human infections has been identified in Mexico, China, 
Japan, Korea, Sweden, Norway, Spain, the Netherlands, and the United Kingdom (33). In 
CTX-M-14 producing E. coli isolates from urinary tract infections in a Korean study, ST38 
was the second most commonly occurring sequence type (33). ST38 has previously been 
predominately associated with urinary tract infections (194). ESBL producing ST38 E. 
coli have also been obtained from other sources including water, pets and asymptomatic 
faecal carriage in humans in Switzerland, Germany, the Netherlands, Japan, and the 
United Kingdom (22,30,33,36,155,161,162,194). 
 




 NON-ESBL ANTIMICROBIAL DRUG RESISTANCE GENES 
Nullarbor used abricate (v.0.4) and resfinder to screen the SPAdes assembly for 
antimicrobial resistance genes. Due to this, the resistance genes identified depend on the 
assembly generated and are limited by the library of resfinder. Partial hits were not 
considered for this analysis. The presence of a resistance gene does not necessarily 
result in phenotypic resistance to an antibiotic. ESBL E. coli, particularly ST131, 




A dfrA gene was identified in most isolates in this study (41/66, 62.1%). This was 
consistent with the New Zealand nationwide 2016 ESR survey which identified a dfrA 
gene in 197/297 (66.3) E. coli isolates examined. A high incidence of dfrA genes in ESBL 
E. coli has also been reported internationally (14,159,195-198). The predominance of 
dfrA17 over dfrA1 seen in Otago (27/41, 65.9% and 6/41, 14.6% respectively), has also 
been seen internationally in Africa, Lebanon, Denmark, Netherlands, Korea, Australia 
and China (159,196,198). Though the opposite has been seen in other countries such as 
Spain, Portugal, and France (196). dfrA12, the other dfrA allele found in Otago has also 
been previously identified in China in ESBL E. coli isolated from humans and livestock 
(198,199).   
 
 
The percentage of aminoglycoside modifying enzyme encoding genes identified in Otago 
(49/66, 74.2%) was also similar to the percentage found nationwide in the 2016 ESR 
survey 213/297 (71.7%). This high prevalence of aminoglycoside resistance genes (to 
gentamicin, streptomycin, spectinomycin, and kanamycin) has been observed in 
countries such as Canada, Australia, China (Hong Kong), the United Kingdom, India, as 
well as various African and European countries (3,4,14,17, 197,199-201).  An 
association between gentamicin resistance genes and ST131 has been observed in 
Canada, Australia, Spain and the United Kingdom (3,4,14,17, 197,199-201). In our study 
15/29 or 51.7% of isolates encoding resistance to gentamicin were ST131.    
 





Plasmid mediated fluoroquinolone resistance genes occurred in 14/66 (21.2%) of 
isolates in Otago, and a similar incidence was seen in the ESR 2016 survey (70/297, 
23.6%). Fluoroquinolone resistance associated with ESBL production has been reported 
internationally, in North America, Europe, Asia, Latin America, South Africa, the Middle 
East,  and in the South Pacific, though incidence rates have varied from 6-79% 
(3,15,159,201-205).  The incidence rates observed in Otago (21.2%) are similar to those 
reported overall in the South Pacific (23.5%) (202). The qnrA gene, identified in all 
continents except South America, has been associated with CTX-M-14; none of the 
isolates found in Otago expressed this combination (15,206). In Otago qnrS and qnrB 
alleles were observed, though with a very small incidence (4/66). In studies in Vietnam 
and France both qnrS and qnrA were identified, and in recent European surveys qnrS 
was found to be more common than qnrA (206). qnrB has been associated with CTX-M-
15 or SHV-12 genes in international reports (15,207). In Otago both qnrB carrying 
isolates also carried SHV-12 genes. Combined resistance to aminoglycosides and 
quinolones in ESBL E. coli has been reported internationally (Europe, the Americas, and 
Asia [China and India]) (3,14,200,201,207). CTX-M-15 and ST131 have previously been 
associated with aac(6′)-Ib-cr, which encodes resistance to quinolones as well as some 
aminoglycosides (tobramycin, gentamicin) in the USA, Europe, and South Africa 
(14,15,203,205,207,208). This was also observed in Otago with 8/10 (80%) isolates 
encoding aac(6′)-Ib-cr also encoding CTX-M-15 (the other two encoding CTX-M-27) and 
7/10 (70%) were ST131. 
 
 
High rates of tetracycline resistance genes were observed in Otago (39/66, 59.1%), 
similarly to international reports in Asia and Africa  (198,199).  
 
 
We identified 3 isolates carrying fosA genes which encode resistance to fosfomycin; no 
genes of this type were identified in E. coli in the ESR survey in 2016. This resistance 
gene has however been reported worldwide (Europe, Asia, South America, and the 
Middle East) in ESBL E. coli isolates with incidence ranging from 0-19% in humans and 
livestock (205,209,210). Colistin resistance genes, which had been identified in ESBL E. 
coli human and environmental sources in other countries (albeit in small numbers), 




were not observed both in Otago in my study and nationwide in the ESR survey, 
although there was a portion of a mcr-1 gene in one isolate (211).  
 
 
MDR genes have previously been reported to occur on the same plasmid as CTX-M 
genes, constituting “resistance islands” (38,39). This was not assessed in this study but 
may be interesting for future studies, which can use the hybrid plasmid assemblies 
produced by this study to delineate the genetic context of non-ESBL resistance genes.  
 
 
 Comparison with Phenotype 
In the NZ ESR survey chromosomally mediated fluoroquinolone resistance 
(chromosomal mutations in gyrA and parC) occurred in a majority of the isolates 
(181/297 (60.9%)) while plasmid mediated fluoroquinolone resistance occurred in only 
70/297 (23.6) of isolates (13). Chromosomally mediated quinolone resistance was not 
assessed in my study. This would likely account for the high percentage (38/51, 74.5%) 
of isolates which showed phenotypic resistance to ciprofloxacin but had no detectable 
quinolone (plasmid mediated) resistance gene. This phenomenon of chromosomal 
quinolone resistance in ESBL E. coli has also been observed overseas (India, USA, 
Netherlands) in human, animal and environmental specimens (208,212). In my study a 
dfrA gene was identified in 90% of the isolates reported to be trimethoprim resistant. 
The 2016 New Zealand ESR survey had a similar high rate of congruence between 
genotype and phenotype at 87.9% (13). Future studies on the phenotypic resistance to 
tetracyclines and fosfomycin for this set of isolates would be useful to determine the 
association between phenotypic expression of resistance and resistance genes. 
 
 




 ESBL-ENCODING PLASMID TYPES   
Plasmid transmission has been important in the spread of ESBL E. coli (18). ESBL-
encoding plasmids were isolated from 41 of 66 (62.1%) ESBL E. coli. The most common 
plasmid types were IncF plasmids (22/41, 53.7%). IncF plasmids are diverse, with 
multiple replicon types such as FIA, FIB, and FII. In this study most of the ESBL carrying 
IncF plasmids were IncFIA/IncFII (9/22, 40.9%) and IncFII (10/22, 45.5%) followed by 
IncFIA (2/22, 9.1%) and IncFIB/IncFII (1/22, 4.5%). 
 
 
IncF plasmids have a narrow host-range but are well adapted to Enterobacteriaceae and 
show high conjugative ability and high transmission rates among Enterobacteriaceae 
(4,14,15,19,50,51,60). IncF plasmids also have a propensity to acquire multiple 
resistance genes, which allows co-selection (4,14,15,19,50,51,60). IncF plasmids 
(including IncFIB, IncFIA, IncFI and IncFII) are the most common ESBL carrying 
plasmids across all CTX-M-groups worldwide (the Americas, Europe, Africa, and Asia) 
(14,19,35,50,51,166,191,197,213-218). The results of my study are consistent with 
these international reports, with 65.6% (21/32) of CTX-M encoding plasmids typing as 
IncF. Internationally (North America, Africa, and Europe [Germany, Norway, Czech 
Republic]), a strong association between CTX-M-15 and IncF plasmids (namely IncFII 
and IncFIA/IncFIB multi-replicon plasmids) has been reported 
(14,19,66,191,197,212,218-221). In contrast, in this study CTX-M-15 was rarely 
associated with IncF plasmids (1/9, 11.1%). Instead, IncF plasmids most commonly 
carried CTX-M-14 and CTX-M-27 genes.   
 
 
Almost all CTX-M-27 genes were carried on IncF plasmids; only 1 of 16 (6.25%) CTX-M-
27-encoding plasmids was non-IncF (IncB/O/K/Z). Specifically, these IncF plasmids 
were IncFII, IncFIA, and IncFIA/IncFII plasmids. An association of CTX-M-27 with IncF 
plasmids has been reported in other countries. A study in Japan found an association 
between CTX-M-27 and IncF plasmid types IncFII, IncFIA, and IncFIB (155). In a study in 
China CTX-M-27 was associated with FII/FIA/FIB in E. coli from animal sources (213). In 
Vietnam CTX-M-27 was found in plasmid types IncFI, IncFIA, IncFIA/IncFII, 




IncFII/IncFIB/IncL1 (listed in descending order of incidence) in E. coli from both human 




A greater variety of plasmids carried CTX-M-14, with 3 of 8 (37.5%) being non-IncF 
plasmids. CTX-M-14 encoding plasmids were IncFII, Inc FIA, IncFIA/IncFII, IncB/O/K/Z, 
and IncI1. In international reports CTX-M-14 has also been found to be carried on a 
variety of plasmid types, including on IncF (Hong Kong, Korea and France), IncK (Spain 
and the United Kingdom) and IncI1 (Uruguay) (19,22,50,51,192,214,217). 
 
 
In this study, CTX-M-15 was carried mostly on IncI1 plasmids (4 of 9, 44.4%). CTX-M-15 
carrying IncI1 plasmids have previously been described in the USA, Vietnam, China, and 
Germany (14,35,66,212,214,222,223). IncI1 was the third most common plasmid type 
found in Otago in this study and was also found carrying CTX-M-55, CTX-M-14, and 
TEM/SHV. IncI1 plasmids are of particular interest as they are highly transmissible; they 
are globally spread among E. coli populations from both humans and animals and appear 
to be widely distributed among different members of the Enterobacteriaceae family (42). 
However, it should be noted that in this study, 3 isolates where the plasmid 
incompatibility type was not able to be determined carried CTX-M-15 genes. CTX-M-15 
was also carried on IncFIA/IncFII and Col156 plasmids. CTX-M-15 has been found on 
IncHI2, IncK, IncX, IncN, IncA/C, and ColBS512 in other studies, if less commonly than on 
IncF plasmids (14,35,212,214,216,222). 
 
The higher incidence of IncF plasmids encoding CTX-M-27 compared to IncF plasmids 
encoding CTX-M-15 parallels the association of ST131 with CTX-M-27 rather than CTX-
M-15 in this study, as discussed above. A strong relationship between ST131 and IncF 
epidemic plasmids (especially FIA and FII replicon types) has been seen internationally 
(34,216,224). This is also seen in this set of isolates, with most (12/17) ST131 carrying 
ESBL genes on IncF plasmids, albeit not encoding CTX-M-15 (224). 
 
Multireplicon plasmids were common in our set of isolates. In fact, the most commonly 




found plasmid type was IncFIA/IncFII multireplicon plasmids (equal in number to 
IncFII). We also described a single IncFIB/IncFII and a single IncN/IncX4 plasmid. 
Multireplicon plasmids harbouring IncFII in addition to IncFIA and/or IncFIB have 
previously been described extensively as well as IncFIA/IncFIB plasmids 
(19,53,216,217,224). Conversely, there have been reports from Turkey, Tanzania, 
Germany, Egypt, and India, of high incidence of IncFIA and IncFIB plasmids (alone and in 
combination), with low rates of IncFII, carrying different CTX-M types (53). IncFII 
plasmids are of interest having been identified in environmental and animal sources 
(225). 
 
An IncN/X4 plasmid encoded CTX-M-55. IncN is important as a broad host-range 
plasmid type, with high conjugation frequency, and has been found in the bacterial flora 
of humans, animals and the environment, making it conducive to the spread of ESBL 
genes (58,217). It has also been associated with MDR (58,217). CTX-M-55 was also 
carried on IncI1 and IncX1 plasmids in this study.  CTX-M-55 has previously been 
associated with IncFII, IncFIA, IncHI2, and IncI1 (35,213,220). 
 
SHV-type ESBLs have also been identified on a variety of plasmids, from narrow range 
(IncF, IncI1, and IncX3), to broad range (IncA/C, IncHI2) (59). In this study SHV 
plasmids were all narrow range; being mostly IncX3 (four isolates) and one IncFII/FIB. 
IncX is important as it is associated with MDR (217).   
 
 
A further two plasmids, which encoded a broad spectrum β-lactamase gene (TEM-1B) 
and an inhibitor resistant β- lactamase gene (TEM-81), were carried on IncFII/FIA and 
an untypeable plasmid respectively. This is in contrast to previous studies where TEM-




Four plasmids were not able to be typed in this study. One of these was not able to be 
completed using the plasmid assembly pipeline. This may be due to insufficient quality 




of the MinION reads, resulting in an incomplete assembly which lacked the sequence 
regions used for plasmid typing. The inability to type the other three completed 
plasmids may be due to the natural mutations and rearrangements of plasmids 
occurring in the sequence regions used for plasmid typing. Many other studies have 
reported plasmids which were designated untypeable (217,226). 
 
 INSERTION SEQUENCES ASSOCIATIONS 
Mobile genetic elements can mediate the movement of resistance genes between 
plasmids (2,14,38). In this study the insertion sequences surrounding the ESBL genes 
were identified. Overall, significant diversity was seen. There were 13 different insertion 
sequence combinations upstream and 12 downstream. Each ESBL gene had many 
different surrounding insertion sequences, although some common insertion sequences 
as well as associations between ESBL genes and insertion sequences were seen.  
 
There were differences seen in the genetic context of different groups of ESBL genes. 
The association of downstream orf477 (with or without an intact or truncated Tn3 
transposon downstream) with group 1 CTX-M genes has been observed in other studies 
in isolates from humans and animals (14,66,216,227,228). The occurrence of IS26 
downstream of orf477, seen in this study, has also been previously observed in a study 
conducted in Spain (229). The exclusive association of Group 9 CTX-M genes (CTX-M-14 
and CTX-M-27) with IS903D downstream has also previously been reported globally 
(25,66,191,216,229,230). These reports also found a varying presence of IS26 
downstream of IS903D, and a varying presence of iroN-Tn3-IS26 downstream of IS903D 
(25,66,191,216,229,230). TEM-1B flanked by tnpR, tnpA, Tn2 and IS26 has been 
previously observed (42). IS3000 has previously been observed in the genetic context of 
group 9 CTX-M genes, however in this study IS3000 only appeared upstream of SHV 
ESBL genes (19). 
 
ISEcp1 and IS26 insertion sequences were commonly seen in the genetic context of all 
CTX-M genes seen in this study. ISEcp1 and IS26 are well documented as the most 




common elements associated with CTX-M-genes (19,22,66,191,215,216,229,231-233). 
ISEcp1 occurred upstream (5’) of all CTX-M genes, while the presence of IS26 varied. 
IS26 occurred less commonly upstream of CTX-M-14 (25%, 2/8) and CTX-M-15 (22%, 
2/9) than of CTX-M-27 (94%, 15/16) and CTX-M-55 (50%, 2/4). The IS26-ISEcp1 
element occurred in 94% of CTX-M-27 isolates (15/16), in contrast 2/4 CTX-M-55 
isolates (50%) had this element, with only one occurrence in  CTX-M-14 isolates (1/8, 
12.5%) and CTX-M-15 isolates (1/8, 12.5%). This pattern has been observed in a 
previous large-scale study in Japan, though the study did not assess for the presence of 
TnA, which occurred upstream of the IS26-ISEcp1 element in most CTX-M-27 isolates 
(14/16, 87.5%) in Otago (25). The IS26-ISEcp1 element has also previously been found 
to be associated with ST131 and IncF plasmids (216,229). However, in this study only 
the CTX-M-27 ST131 isolates (10/11, 90.9%) and 1 CTX-M-55 ST131 (1/1) isolate had 
this element (11/17, 64.7% of ST131 in total). None of the ST131 isolates carrying CTX-
M-14 or CTX-M-15 genes contained this structure. In addition, IS26-ISEcp1 was also 
present in all other STs which carried CTX-M-27. Nevertheless, the frequency of IS26 
presence suggests IS26-mediated transposition of CTX-M genes (216).  IS26 also 
commonly appeared downstream (3’) of the CTX-M gene (23/43, 53.5%), whereas 
ISEcp1 was only found upstream, consistent with other studies (25,216,229). 
 
 
In comparison to CTX-M-14, which mostly had only ISEcp1 upstream (6/8, 75%), CTX-
M-15 also had a TnA sequence upstream of ISEcp1 (4/8, 50%); this difference has 
previously been observed (216).  The varying occurrence of Tn3 structures upstream or 
downstream of ESBL genes in other instances in this study has also been observed in 
other studies (215,216). Tn3-type transposons are thought to be a target entry point for 
integration of ESBL genes and surrounding insertion sequences into the plasmid (216). 
ISCR1 is an insertion sequence that has been important in the dissemination of CTX-M 
genes but was not identified in any isolates in this study (19,215). 
 
 
There were differences downstream of the group 9 CTX-M isolates as well. With IS903D-
iroN-Tn3-like-IS26-TnA (designated S) being found only in CTX-M-27 isolates (4/16, 
25%). However, the same structure without the downstream TnA (designated T) was 




found in both CTX-M-14 (2/8, 25%) and CTX-M-27 (2/16 12.5%). This downstream 
structure (IS903D-iroN-Tn3-like-IS26) has been previously described in Japan also with 
low incidence, but only in the context of CTX-M-27 (25). In summary, the TnA-IS26-
ISEcp1-CTX-M-27-IS903D-IS26 unit (E-V) which was the most common genetic context 
of CTX-M-27 has been observed in previous studies, though some studies did not assess 
the presence of TnA as discussed previously (25,216). An additional isolate with E-CTX-
M-27-V had bilateral presence of IS1b; to my knowledge, this has not been seen in the 
context of CTX-M-27 in previous published studies. ISEcp1-CTX-M-14-IS903D unit (A-W) 
was the most common in CTX-M-14.  
 
 
In group 1 isolates, all four CTX-M-55 isolates had different insertion sequences. Though 
3/4 (75%) CTX-M-55 had orf477 only downstream of the CTX-M gene, with only one 
orf477-TnA occurrence, upstream insertion sequences differed. In contrast in CTX-M-15, 
the orf477 gene only occurred in combination with either TnA (5/8, 62.5%) or Tn3-IS26 
(3/8, 37.5%) unit. In summary, only TnA-ISEcp1-CTX-M-15-orf477-TnA (B-Y) 
(3/8,37.5%) and ISEcp1-CTX-M-15-orf477-TnA (A-Y) (2/8, 25%) occurred in more than 
one isolate among CTX-M-15 isolates. The ISEcp1-CTX-M-15-orf477 and ISEcp1-CTX-M-
55-orf477 units have been described in previous studies (25,216,234,235). 
 
 
All four SHV-12 isolates had different insertion sequences. These included an isolate 
with only IS3000, ISEhe3, and IS26 upstream and no identified downstream insertion 
sequences, an IS26-SHV-12-deoR isolate (L-P), a TnA-IS26-SHV-12-deoR (I-P) isolate, and 
an IS26-SHV-12-TnA (L-O) isolate. IS26-SHV-12-deoR units have been identified in past 








 OVERALL GENETIC DIVERSITY 
While there were some observed associations between ESBL genes, their genetic context 
(including plasmid type), E. coli MLST type, and clusters on the pangenome, as discussed 
above, overall considerable genetic diversity was seen. All the TEM genes were different 
in terms of MLST, plasmid type, and genetic context. The four CTX-M-55 isolates were all 
different MLSTs, had different genetic contexts, and were carried on plasmids of three 
different incompatibility types. While there were three CTX-M-15/ST131 isolates, they 
differed in their genetic contexts. The ESBL encoding plasmids of the three CTX-M-
14/ST405 isolates were of different incapability types and had differing insertion 
sequences around the CTX-M-14 gene. Furthermore, where the plasmid type, genetic 
context and ESBL gene were the same, the MLST type of the isolate varied.  For example, 
the three IncI1/B-Y/CTX-M-15 plasmids were from ST131, ST162, and ST3036 isolates. 
In another instance the two IncB/O/K/Z/A-W/CTX-M-14 plasmids were from ST 69 and 
ST405 isolates. Among the four SHV-12 isolates, there were three isolates which were 
ST636, carried the SHV gene on plasmids of incompatibility type IncX3, however the 
insertion sequences differed (L-O, L-Q, and H-). In the CTX-M-27 isolates there were 
some notable clones. Clusters of two (2/66, 3.0%) CTX-M-27/ST131/IncFII/ET isolates, 
three (3/66, 4.5%) ST38/IncFII/ES isolates, and six (6/66, 9.1%) ST131/IncFIA-
IncFII/EV isolates were identified. The other 5 CTX-M-27 isolates differed in MLST, 
plasmid incompatibility type and/or insertion sequences. 
 
 
This observed low level clustering, with the overall population of ESBL E. coli strains 
encoding multiple enzyme types, sequence types, genetic contexts, and plasmid types, 
indicates multiple introductions into the Otago population with limited evidence of 
horizontal transmission (39,74). This is in contrast to a limited number of point source 
introductions and onward transmission of highly transmissible drug resistant strains 
that would have resulted in a few dominant strains of the same MLST profile, carrying 




These multiple introductions could be from numerous sources. Inadequate, 




unnecessary, or overuse of antibiotics in treatment, overuse of antibiotics in agriculture 
could all constitute selection pressures for the mobilization of antibiotic resistance 
genes (68,239,240,241,242). Recent studies have shown that the low antibiotic 
concentrations that have been found in environmental residues (such as hospital and 
wastewater effluent) are sufficient for the positive selection of ESBL resistance (i.e. 
higher than the minimum selective concentration) (68,240,242). Many of the ESBL and 
associated sequence types and plasmids types found in this study have been found 
commonly from animal and environmental sources in international studies as discussed 
previously. Future studies on the presence of ESBL genes in the environment, animals, 
and asymptomatic faecal carriage in humans could be important for the elucidation of 
potential reservoirs. The finding that the increase in ESBL urinary tract infection 
incidence in Otago is largely not due to the transmission of highly virulent clones is also 
important to avoid inappropriate outbreak management (242). 
 
 
Duplicate isolates, that is isolates from the same patient from different periods of time, 
were  excluded as they had not been cryopreserved, so determination of mutation rate 
was not possible. This would have allowed us to observe any change over time in the 
infecting strain, and the rate of change in the genome, in order to accurately estimate the 
molecular clock for E. coli in vivo (74). 
 
 
Molecular evidence of clonal linkage merely provides support to epidemiological 
evidence (39). For example, inappropriate antibiotic use in medicine or agriculture 
exerts a selective pressure, which may result in the emergence and spread of antibiotic 
resistance (4,15,38,43). Further epidemiological evaluations, which were not carried out 
in this study, could help identify person-to-person contact or common exposure to 
epidemiological sources. Although, the ESR nationwide study in 2016 on ESBL 
Enterobacteriaceae found no significant association between patient demographics and 
phylogeny or ESBL genes, this was very high level and lacks granularity compared to 
contact network epidemiology and molecular studies (13).  
 
 






This study provides up to date information on the ESBL E. coli causing urinary tract 
infections in Dunedin and the genetic context of resistance. The development of a 
bioinformatic pipeline for the hybrid assembly of Illumina short read WGS and MinION 
long read sequences of plasmids allowed the full genetic characterisation of isolates 
easily and quickly. Taking into account ESBL gene, sequence type, plasmid type, and 
insertion sequences all fully characterised isolates showed high diversity, with only 2 
small clusters of clonal isolates. Instead of the expansion of one or a few bacterial clones, 
and transmission of mobile genetic element(s) encoding multiple resistance genes 
between strains, there appear to have been multiple introductions of ESBL genes into 
Otago, a low prevalence area. This raises important questions about the reservoir of 
ESBL genes and the vehicle(s) of transmission. Further combined laboratory and 
epidemiological studies will be required to investigate this. This data can inform the 
need for infection control and/or antibiotic policy assessments in Otago and potentially 
other low prevalence areas.   
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 APPENDIX A  
  
• Figure 1  
Albacore run on raw signal MinION fast5 output files  
"C:\Program Files\OxfordNanopore\ont-Albacore\read_fast5_basecaller.exe" --
flowcell FLO-MIN106 --kit SQK-RBK108 --barcoding --recursive --
output_format fast5,fastq --input directory_of_fast5_files --
save_path directory_for_output --worker_threads 4  
 
 
• Figure 2  
.sh file written in nano  
nano Minion_read_1.sh  
for file in *.fastq; do  




• Figure 3  
 Miniasm/Minimap on MinION long reads  
/APPS/minimap/minimap -Sw5 -L100 -m0 -
t8 Minion_reads.fastq Minion_reads.fastq |gzip -1 > Minion_reads.paf.gz  
/APPS/miniasm/miniasm -f Minion_reads.fastq Minion_reads.paf.gz > Minion_reads.gfa  
awk '/^S/{print ">"$2"\n"$3}' Minion_reads.gfa | fold > Minion_reads.fa  
grep ">" Minion_reads.fa | wc -l  
  
SPAdes on paired Illumina short reads and the Miniasm/Minimap long read only 
assembly  
spades.py -plasmid -1 illumina_shortreads_forward.fastq.gz -
2 Illumina_shortreads_reverse.fastq.gz  --untrusted-contigs Minion_reads.fa -
o miniasm_spades_hybrid_assembly  
 
• Figure 4  




run Miniasm/Minimap on long reads to build long read only assembly  
/APPS/minimap/minimap -Sw5 -L100 -m0 -t8 BC01.fastq BC01.fastq | gzip -1 > 
BC01.paf.gz  
/APPS/miniasm/miniasm -f BC01.fastq BC01.paf.gz > BC01.gfa  
awk '/^S/{print ">"$2"\n"$3}' BC01.gfa | fold > BC01.fa  
grep ">" BC01.fa | wc -l  
  
OR use sed to flatten the fastq to fasta   
sed  '/^@/!d;s//>/;N’ BC01.fq > BC01.fa  
 
 
• Figure 5  
Bowtie2 to build an index  
bowtie2-build -f BC01.fa index_B4R4BC01  
Run bowtie2 to filter reads  
bowtie2 –q --very-sensitive-local -x index _B4R4BC01 -1 shortread1.fastq.gz  -2 
shortread2.fastq.gz --al-conc ./mappedshortread.fq -S test.sam --no-unal -N 1  
 
 
• Figure 6  
Unicycler command  
Unicycler -mode normal -1 mappedshortread.1.fq -2 mappedshortread.2.fq -l 



















• Figure 7  
 
 




 APPENDIX B 




The  accompanying HTML file contains the Nullarbor report which shows  the  sequence 
assembly metrics and annotation, MLST, species identification, resistome, core genome 
phylogeny and pan genome phylogeny.   
 
Filename: 
Supplemental_data_Nullarbor 
